US20090047254A1 - Bacteriophage and their uses - Google Patents
Bacteriophage and their uses Download PDFInfo
- Publication number
- US20090047254A1 US20090047254A1 US12/216,074 US21607408A US2009047254A1 US 20090047254 A1 US20090047254 A1 US 20090047254A1 US 21607408 A US21607408 A US 21607408A US 2009047254 A1 US2009047254 A1 US 2009047254A1
- Authority
- US
- United States
- Prior art keywords
- bacteriophage
- seq
- dna sequence
- genome
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001515965 unidentified phage Species 0.000 title claims abstract description 209
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 94
- 241000894006 Bacteria Species 0.000 claims abstract description 67
- 230000002934 lysing effect Effects 0.000 claims abstract description 37
- 230000028744 lysogeny Effects 0.000 claims abstract description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 144
- 108700026244 Open Reading Frames Proteins 0.000 claims description 102
- 108091033319 polynucleotide Proteins 0.000 claims description 55
- 102000040430 polynucleotide Human genes 0.000 claims description 55
- 239000002157 polynucleotide Substances 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 52
- 239000012634 fragment Substances 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 43
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 38
- 206010000496 acne Diseases 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 241000894007 species Species 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 229940088710 antibiotic agent Drugs 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 208000020154 Acnes Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 230000001320 lysogenic effect Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 229920000936 Agarose Polymers 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 230000002101 lytic effect Effects 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000001066 phage therapy Methods 0.000 description 7
- 208000035143 Bacterial infection Diseases 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 101710115267 ATP synthase protein MI25 Proteins 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 4
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 101710198378 Uncharacterized 10.8 kDa protein in cox-rep intergenic region Proteins 0.000 description 4
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 4
- 101710134973 Uncharacterized 9.7 kDa protein in cox-rep intergenic region Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 101000977065 Acidithiobacillus ferridurans Uncharacterized 11.6 kDa protein in mobS 3'region Proteins 0.000 description 3
- 101000787133 Acidithiobacillus ferridurans Uncharacterized 12.3 kDa protein in mobL 3'region Proteins 0.000 description 3
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 3
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 3
- 101000708563 Acidithiobacillus ferrooxidans Uncharacterized 9.0 kDa protein in mobE 3'region Proteins 0.000 description 3
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 3
- 101000743047 Autographa californica nuclear polyhedrosis virus Protein AC23 Proteins 0.000 description 3
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 3
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 3
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 3
- 101000827603 Bacillus phage SPP1 Uncharacterized 10.2 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 3
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 3
- 101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 3
- 101000765606 Bacillus subtilis (strain 168) FlaA locus uncharacterized protein YlxG Proteins 0.000 description 3
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 3
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 3
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 3
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 3
- 101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 3
- 101000861180 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0147 Proteins 0.000 description 3
- 101000861181 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0148 Proteins 0.000 description 3
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 3
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 3
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 3
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 3
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 3
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 3
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 3
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 3
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 3
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 3
- 101710126256 Hydrolase in agr operon Proteins 0.000 description 3
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 3
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 3
- 102100024407 Jouberin Human genes 0.000 description 3
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 3
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 3
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 3
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 3
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 3
- 101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 3
- 101000977786 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 9.7 kDa protein in PE 3'region Proteins 0.000 description 3
- 101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 3
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 3
- 101000850960 Pseudomonas phage Pf1 3.2 kDa protein Proteins 0.000 description 3
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 3
- 102000009661 Repressor Proteins Human genes 0.000 description 3
- 108010034634 Repressor Proteins Proteins 0.000 description 3
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 3
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 3
- 101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 description 3
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 3
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 3
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 3
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 3
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 3
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 3
- 206010042566 Superinfection Diseases 0.000 description 3
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 3
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 3
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 3
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 101710136524 X polypeptide Proteins 0.000 description 3
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 3
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 3
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 3
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 3
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229960005280 isotretinoin Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 244000005706 microflora Species 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 2
- 101000748061 Acholeplasma phage L2 Uncharacterized 16.1 kDa protein Proteins 0.000 description 2
- 101000818123 Acholeplasma phage L2 Uncharacterized 17.2 kDa protein Proteins 0.000 description 2
- 101000818089 Acholeplasma phage L2 Uncharacterized 25.6 kDa protein Proteins 0.000 description 2
- 101000827329 Acholeplasma phage L2 Uncharacterized 26.1 kDa protein Proteins 0.000 description 2
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 2
- 101000818108 Acholeplasma phage L2 Uncharacterized 81.3 kDa protein Proteins 0.000 description 2
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 2
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 2
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 2
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 2
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 2
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 2
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 2
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 2
- 101000748781 Anthoceros angustus Uncharacterized 3.0 kDa protein in psbT-psbN intergenic region Proteins 0.000 description 2
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 2
- 101000770875 Autographa californica nuclear polyhedrosis virus Uncharacterized 14.2 kDa protein in PK1-LEF1 intergenic region Proteins 0.000 description 2
- 101000781183 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.4 kDa protein in IAP1-SOD intergenic region Proteins 0.000 description 2
- 101000847476 Autographa californica nuclear polyhedrosis virus Uncharacterized 54.7 kDa protein in IAP1-SOD intergenic region Proteins 0.000 description 2
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 2
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 2
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 2
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 2
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 2
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 2
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 2
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 2
- 101000736075 Bacillus subtilis (strain 168) Uncharacterized protein YcbP Proteins 0.000 description 2
- 101000736076 Bacillus subtilis (strain 168) Uncharacterized protein YcbR Proteins 0.000 description 2
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 2
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 2
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 2
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 2
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 2
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 2
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 2
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 2
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 2
- 101000736909 Campylobacter jejuni Probable nucleotidyltransferase Proteins 0.000 description 2
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 2
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 2
- 101000947615 Clostridium perfringens Uncharacterized 38.4 kDa protein Proteins 0.000 description 2
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 2
- 241001508000 Corynebacterium bovis Species 0.000 description 2
- 241001464974 Cutibacterium avidum Species 0.000 description 2
- 241001464975 Cutibacterium granulosum Species 0.000 description 2
- 101000792449 Cyanophora paradoxa Uncharacterized 3.4 kDa protein in atpE-petA intergenic region Proteins 0.000 description 2
- 101150026402 DBP gene Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102100024101 DnaJ homolog subfamily C member 28 Human genes 0.000 description 2
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 2
- 101000964391 Enterococcus faecalis UPF0145 protein Proteins 0.000 description 2
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 2
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 2
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 2
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 2
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 2
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 2
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 2
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 2
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 2
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 2
- 101000912350 Haemophilus phage HP1 (strain HP1c1) DNA N-6-adenine-methyltransferase Proteins 0.000 description 2
- 101000933958 Haemophilus phage HP1 (strain HP1c1) Major capsid protein Proteins 0.000 description 2
- 101000743338 Haemophilus phage HP1 (strain HP1c1) Probable head completion/stabilization protein Proteins 0.000 description 2
- 101001066788 Haemophilus phage HP1 (strain HP1c1) Probable portal protein Proteins 0.000 description 2
- 101000854890 Haemophilus phage HP1 (strain HP1c1) Probable terminase, ATPase subunit Proteins 0.000 description 2
- 101000743335 Haemophilus phage HP1 (strain HP1c1) Probable terminase, endonuclease subunit Proteins 0.000 description 2
- 101000748063 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 11.1 kDa protein in rep-hol intergenic region Proteins 0.000 description 2
- 101000758973 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 11.3 kDa protein in lys 3'region Proteins 0.000 description 2
- 101000758963 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 12.7 kDa protein in lys 3'region Proteins 0.000 description 2
- 101000976893 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 14.1 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- 101000818057 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 14.9 kDa protein in rep-hol intergenic region Proteins 0.000 description 2
- 101000818121 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 18.2 kDa protein in rep-hol intergenic region Proteins 0.000 description 2
- 101000786896 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in rep-hol intergenic region Proteins 0.000 description 2
- 101000786921 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 26.0 kDa protein in rep-hol intergenic region Proteins 0.000 description 2
- 101000768945 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 7.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
- 101000748060 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.3 kDa protein in rep-hol intergenic region Proteins 0.000 description 2
- 101000977016 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
- 101000623276 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiBIM 5'region Proteins 0.000 description 2
- 101000623175 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiCIIM 5'region Proteins 0.000 description 2
- 101000626850 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiEIM 5'region Proteins 0.000 description 2
- 101000748192 Herpetosiphon aurantiacus Uncharacterized 15.4 kDa protein in HgiDIIM 5'region Proteins 0.000 description 2
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 2
- 101001053999 Homo sapiens DnaJ homolog subfamily C member 28 Proteins 0.000 description 2
- 101001028836 Homo sapiens M-phase-specific PLK1-interacting protein Proteins 0.000 description 2
- 101000652805 Homo sapiens Protein shisa-8 Proteins 0.000 description 2
- 101000820589 Homo sapiens Succinate-hydroxymethylglutarate CoA-transferase Proteins 0.000 description 2
- 101000667300 Homo sapiens WD repeat-containing protein 19 Proteins 0.000 description 2
- 101100100297 Human herpesvirus 8 type P (isolate GK18) TRM3 gene Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 2
- 101000578717 Klebsiella pneumoniae Mannose-1-phosphate guanylyltransferase Proteins 0.000 description 2
- 101000957786 Klebsiella pneumoniae Phosphomannomutase Proteins 0.000 description 2
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 2
- 101001015100 Klebsiella pneumoniae UDP-glucose:undecaprenyl-phosphate glucose-1-phosphate transferase Proteins 0.000 description 2
- 101000790838 Klebsiella pneumoniae UPF0053 protein in cps region Proteins 0.000 description 2
- 101000790837 Klebsiella pneumoniae Uncharacterized 18.9 kDa protein in cps region Proteins 0.000 description 2
- 101000790844 Klebsiella pneumoniae Uncharacterized 24.8 kDa protein in cps region Proteins 0.000 description 2
- 101000790840 Klebsiella pneumoniae Uncharacterized 49.5 kDa protein in cps region Proteins 0.000 description 2
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 2
- 101000790842 Klebsiella pneumoniae Uncharacterized 65.4 kDa protein in cps region Proteins 0.000 description 2
- 101000768313 Klebsiella pneumoniae Uncharacterized membrane protein in cps region Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 2
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102100037185 M-phase-specific PLK1-interacting protein Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101000626970 Marchantia polymorpha Uncharacterized 3.3 kDa protein in psbT-psbN intergenic region Proteins 0.000 description 2
- 101000626905 Marchantia polymorpha Uncharacterized 3.8 kDa protein in ycf12-psaM intergenic region Proteins 0.000 description 2
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 2
- 101000804418 Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H) Uncharacterized protein MTH_1463 Proteins 0.000 description 2
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 2
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 2
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 101150101223 ORF29 gene Proteins 0.000 description 2
- 101710087110 ORF6 protein Proteins 0.000 description 2
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 2
- 101100096140 Orgyia pseudotsugata multicapsid polyhedrosis virus SOD gene Proteins 0.000 description 2
- 101000666843 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 24.0 kDa protein Proteins 0.000 description 2
- 101000770899 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 24.3 kDa protein Proteins 0.000 description 2
- 101000781204 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 36.6 kDa protein Proteins 0.000 description 2
- 101000770870 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 37.2 kDa protein Proteins 0.000 description 2
- 101000805098 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 73.1 kDa protein Proteins 0.000 description 2
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 2
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 2
- 101710197985 Probable protein Rev Proteins 0.000 description 2
- 102100040307 Protein FAM3B Human genes 0.000 description 2
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 2
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 2
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 2
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 2
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 2
- 101000748499 Rhodobacter capsulatus Uncharacterized 104.1 kDa protein in hypE 3'region Proteins 0.000 description 2
- 101000748505 Rhodobacter capsulatus Uncharacterized 16.1 kDa protein in hypE 3'region Proteins 0.000 description 2
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 2
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 2
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 2
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 2
- 101000992423 Severe acute respiratory syndrome coronavirus 2 Putative ORF9c protein Proteins 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 2
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 2
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 2
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 2
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 2
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 2
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 2
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 2
- 102100021652 Succinate-hydroxymethylglutarate CoA-transferase Human genes 0.000 description 2
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 2
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 2
- 101000764204 Trieres chinensis Uncharacterized 3.3 kDa protein in rpl11-trnW intergenic region Proteins 0.000 description 2
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 2
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 2
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 2
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 2
- 102100039744 WD repeat-containing protein 19 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960002255 azelaic acid Drugs 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 description 2
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 2
- 229960001625 furazolidone Drugs 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 244000005714 skin microbiome Species 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000502 Acne cosmetica Diseases 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 241001655324 Propionibacteriales Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 101000872823 Xenopus laevis Probable histone deacetylase 1-A Proteins 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- -1 application stick Substances 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 231100000067 mild irritant Toxicity 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229940055009 propionibacterium avidum Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
Definitions
- the invention relates to bacteriophage and their uses. In particular, though not exclusively, it relates to their use in compositions for the treatment of acne.
- Acne vulgaris is one of the most common diseases of the skin and in cases of extreme disfigurement can sometimes have severe consequences for the personality development of young people with ensuing social and economic problems.
- Adolescents suffering from acne show higher levels of anxiety, greater social inhibition and increased aggression compared to non-acne individuals.
- acne is the second highest cause of suicides.
- Acne is an exclusively human disease and a unique condition of human sebaceous follicles of the face, chest and back. Spontaneous regression is common, taking about 15 years to complete. However, in about 5 percent of cases, acne persists beyond the age of 25 years and extends into the fourth and fifth decades of life. The earlier the symptoms start, the more severe is the course of the disease. The prevalence of the disease does not reflect any preference for male or female but usually the course is more severe in males.
- acnes is associated with the onset of the disease; patients with severe acne are significantly more sensitised to P. acnes than normal individuals; the overall immunological status of patients is elevated compared to acne-free individuals of the same age; successful antibiotic treatment reduces the density of P. acnes on the skin; and antibiotic therapeutic failure is associated with the presence of antibiotic resistant P. acnes on the skin of the patient.
- anti-comedonal treatments include retinoids and azelaic acid (topical treatments) and isotretinoin (oral treatments); anti- P. acnes treatments include benzoyl peroxide, azelaic acid, erythromycin, tetracycline and clindamycin (topical treatments) and tetracycline, erythromycin, minocycline and trimethoprim (oral treatments); anti-inflammatory treatments include tetracycline, erythromycin, clindamycin and nicotinamide (topical treatments) and tetracycline, minocycline, trimethoprim and isotretinoin (oral treatments); and anti-seborrhoeic treatments include spironolactone (topical treatments) and DianetteTM and isotretinoin (oral treatments).
- bacteriophage naturally occurring bacterial viruses
- phage the words “bacteriophage” and “phage” are used interchangeably throughout this specification.
- the fact that bacteriophage can specifically infect a bacterial host and rapidly kill it suggested to d'Herelle that this was potentially a very effective way of controlling bacterial infection in man (for review, see “Felix d'Herelle and the Origins of Molecular Biology” William C. Summers (Yale University Press, ISBN 0-300-07127-2)).
- This potential was never fully realised because of the advent of the antibiotic era, but phage therapy has been pursued since then, in many cases successfully, in former states of the USSR and Eastern Europe.
- WO03/080823 discloses a method for generating candidate bacteriophage for use in therapy by mutating temperate bacteriophage and producing a cocktail of phages. This disclosure specifically selects lysogenic phage, observing that for some bacteria they are more numerous and, therefore, easier to isolate than lytic phage. The phage then have to be mutated to produce lytic vir mutants, in order to avoid the problems associated with lysogenic phage as a therapy, as discussed further below. Treatment of P. acnes is mentioned.
- EP0414304 relates to the use of bacteriophage to kill bacteria, including P. acnes .
- bacteriophage capable of lysing multiple strains of P. acnes bacteria and yet which is incapable of lysing a bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium.
- Jong et al (Med. Microbiol. Immunol. 161 (1975) 263-271) describes isolation of P. acnes phage.
- the paper focuses on the classification of the phage and does not disclose a bacteriophage capable of lysing multiple strains of P. acnes bacteria and yet which is incapable of lysing a bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium.
- Puhvel & Reisner (Amer. Soc. Microbiol. 72 (1972) V201) is an abstract relating to the generation of lysogenic phage-resistant strains of P. acnes.
- WO01/51066 relates to the use of bacteriophage to reduce risk of infection or sepsis, particularly in immunocompromised patients.
- the disclosed methodology aims to achieve the numerical reduction or elimination of various members of the body's natural bacterial flora, in order to reduce the chance of them causing disease in immunocompromised patients. This is specifically risk reduction rather than cure and is concerned in particular with infections which complicate conditions such as certain cancers, AIDS and cystic fibrosis and which complicate the condition of transplant patients. No mention is made of treatment of P. acnes.
- U.S. Pat. No. 6,121,036 relates to a purified, host specific, non-toxic, wide host range bacteriophage preparation containing at least two phage.
- the document describes some of the features of an effective phage therapy—that it should be safe, have broad host range and kill a large proportion of bacteria strains—and indicates that such a preparation of appropriate phage could be used to treat P. acnes infections.
- no disclosure is made about which phage are suitable for this purpose or that such safe, lytic, broad host range phage exist for P. acnes.
- WO02/07742 purports to disclose a method for potentiating a wider host range for a phage by cloning tail protein-encoding genes from another phage with different host specificity.
- the document indicates that wide specificity is desirable from a phage therapy point of view but, rather than selecting from naturally occurring phage variants, describes the synthetic construction of a hybrid bacteriophage with dual tail fibre types, therefore having corresponding dual host specificity.
- This specificity is hypothetically extended to apply the invention in the engineering of a phage which can infect not only different species strains but different bacteria within a species and even within different genera.
- US2005/0032036 describes a method for sorting through a phage collection and determining the composition of a phage cocktail in order to optimise broad host range infection and lysis, particularly in reference to Pseudomonas and Staphylococcus strains. No disclosures are made in relation to the field of acne phage therapy.
- WO2005/009451 relates in particular to the use of bacteriophage as a part of a combination therapy with traditional, chemical antibiotics, particularly in the treatment of Pseudomonas aeruginosa infections and particularly in the treatment of bacteria within biofilms. It describes the difficulty in finding phage with sufficiently broad host specificity to be of therapeutic value for treatment of any given infection and advocates the use of multiple bacteriophage types for therapy, whether simultaneously, separately or sequentially. It also indicates that greater virulence in a phage can be induced artificially by genetic manipulation methods to produce phage with broader specificity or greater infection potential. There is no mention of P. acnes , which is not characterised by biofilm formation.
- US2004/0241825 discloses several methods for genetically labelling bacteriophage (with a non-functional stretch of DNA that can be detected by, for example, PCR, enabling identification of the phage), identifying non-cross reacting bacteriophage (a multi-step process to isolate phage against the target host and, from these, isolating bacteriophage which do not infect more than 5% of non-pathogenic, non-target hosts) and, finally, a method for selecting phage that are resistant to genetic modification by host bacteria (which involves infecting bacteria with a sample of bacteriophage, isolating progeny phage and comparing the restriction digest patterns of the original bacteriophage and the progeny to identify any differences that would be indicative of genetic modification). Implicit in this disclosure is the difficulty in identifying suitable candidate bacteriophage for use in a therapy. The application of this methodology to P. acnes is not described:
- a bacteriophage capable of lysing a P. acnes bacterium and incapable of lysing any bacterium which is not P. acnes , and which is incapable of sustaining lysogeny in a bacterium.
- a bacteriophage has the ability to infect a wide range of bacterial strains within a species but with absolute species specificity. This is one of the most important and usually unachievable aims in the development of an effective phage therapy.
- a bacteriophage according to the invention is purely lytic, i.e. incapable of entering the lysogenic phase of the bacteriophage life cycle, a quiescent stage which is undesirable in the creation of an effective therapy and is also unacceptable from a regulatory point of view.
- such a bacteriophage can be used in the treatment of acne.
- No side effects have been reported or are expected in the use of phage therapy, whether delivered systemically, orally or topically.
- the bacteriophage is specific to P. acnes and therefore leaves other members of the skin flora unaffected, reducing the opportunity for the overgrowth of potentially harmful flora.
- the protective nature of the normal resident microflora is therefore maintained.
- the specificity of a phage therapy approach to treatment of acne also eliminates the possibility of drug resistance emerging in other members of the microflora: other antibacterial treatments offer a broad brush stroke approach to eliminating bacteria and therefore, under the appropriate conditions, provide an opportunity for developing drug resistance not only in P.
- a further advantage of bacteriophage treatment is that it is self regulating: as the population of host P. acnes cells reduces, so will the bacteriophage numbers.
- such a bacteriophage can be used as a general prophylactic measure; the use of antibiotics in unprescribed cosmetic products (such as face washes, etc) is undesirable for many reasons relating to safety and the issue of antibiotic resistance.
- the use of the bacteriophage may be effective even against bacterial strains which have become resistant to antibiotics.
- the use of a bacteriophage which can lyse P. acnes but is incapable of sustaining lysogeny has the advantage that the bacteriophage cannot lie dormant within a bacterium, but must lyse the bacterium and hence kill it.
- the bacteriophage lacks the ability to express at least one gene necessary for sustaining lysogeny.
- the term “lacks the ability to express” is intended to indicate that the bacteriophage lacks the ability to produce a fully functional protein product necessary to sustain lysogeny, for example, as the result of one or more point mutations or full or partial deletions of the genome.
- the phage has a genome which lacks all or part of at least one gene necessary for sustaining lysogeny.
- the phage may comprise defects (e.g.
- the phage is preferably naturally occurring and isolated, with the added advantage that artificial mutations need not be introduced into the bacteriophage. Such mutations, whilst not ruled out, could have potentially unknown results which could be harmful to the individual to whom the bacteriophage is administered. If the phage contains artificial mutations, or is otherwise non-naturally occurring, it is still preferred that the phage is obtained in an isolated state.
- the bacteriophage according to this aspect of the invention is capable of lysing a plurality of strains of the P. acnes bacterium.
- the bacteriophage according to this aspect of the invention may be capable of lysing 5 strains of the P. acnes bacterium, preferably at least 10 strains, more preferably at least 16 strains, or at least 17 strains, or at least 18 strains, or at least 19 strains, or at least 20 strains.
- the bacteriophage is capable of lysing at least 21 strains.
- the bacteriophage according to this aspect of the invention is isolated and selected from those phage characterised hereinafter as: 103609; 103672; and 1894.
- the bacteriophage may have a genome which comprises the DNA sequence of SEQ ID NO:3, or a genome having sequence identity of at least 87% with the DNA sequence of SEQ ID NO:3, more preferably sequence identity of at least 88% with that sequence, yet more preferably sequence identity of at least 90% with that sequence, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence.
- the bacteriophage may have a genome comprising a functional fragment of the DNA sequence of SEQ ID NO:3.
- the functional fragment may be selected from within the Open Reading Frames shown in FIG. 2 .
- the functional fragment may comprise a DNA sequence having sequence identity of at least 95% with the DNA sequence of FIG. 6 , preferably sequence identity of at least 96%, more preferably sequence identity of at least 97% with that sequence, most preferably sequence identity of at least 98% or 99% with that sequence.
- the functional fragment comprises the DNA sequence of FIG. 6 .
- the bacteriophage may have a genome which comprises the DNA sequence of SEQ ID NO:4, or a genome having sequence identity of at least 88% with the DNA sequence of SEQ ID NO:4, more preferably sequence identity of at least 89% with that sequence, yet more preferably sequence identity of at least 90% with that sequence, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence.
- the bacteriophage may have a genome comprising a functional fragment of the DNA sequence of SEQ ID NO:4.
- the functional fragment may be selected from within the Open Reading Frames shown in FIG. 3 .
- the functional fragment may comprise a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:7, preferably sequence identity of at least 96%, more preferably sequence identity of at least 97% with that sequence, most preferably sequence identity of at least 98% or 99% with that sequence.
- the functional fragment comprises the DNA sequence of SEQ ID NO:7.
- the bacteriophage may have a genome which comprises the DNA sequence of SEQ ID NO:5, or a genome having sequence identity of at least 88% with the DNA sequence of SEQ ID NO:5, more preferably sequence identity of at least 89% with that sequence, yet more preferably sequence identity of at least 90% with that sequence, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence.
- the bacteriophage may have a genome comprising a functional fragment of the DNA sequence of SEQ ID NO:5.
- the functional fragment may be selected from within the Open Reading Frames shown in FIG. 4 .
- the functional fragment may comprise a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:8, preferably sequence identity of at least 96%, more preferably sequence identity of at least 97% with that sequence, most preferably sequence identity of at least 98% or 99% with that sequence.
- the functional fragment comprises the DNA sequence of SEQ ID NO:8.
- the functional fragment may comprise the DNA sequence of one or more of:
- the functional fragment comprises a DNA sequence which is conserved between all of SEQ ID NO:3, 4 and 5.
- the bacteriophage may have a genome having sequence identity of at least 88% with the genome of the bacteriophage deposited under Accession No. NCIMB 41349, preferably sequence identity of at least 89%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99%.
- the bacteriophage may have a genome having sequence identity of at least 87% with the genome of the bacteriophage deposited under Accession No. NCIMB 41350, preferably sequence identity of at least 88%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99%.
- the bacteriophage may have a genome having sequence identity of at least 88% with the genome of the bacteriophage deposited under Accession No. NCIMB 41351, preferably sequence identity of at least 89%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99%.
- sequence identity is calculated as the percentage of nucleotides present in the smaller of the two sequences to be compared that may also be found in the larger of the two sequences, the nucleotides preferably being arranged in the same order in both sequences.
- the length of the shorter of the two sequences being compared is at least 60% of the length of the longer of the two sequences, more preferably at least 70% of the length, yet more preferably at least 80% of the length and still more preferably at least 90%, 95%, 96% 97% 98% or 99% of the length.
- the sequences to be compared are identical in length.
- the term “functional fragment”, as used throughout this specification, indicates a portion of the full length sequence which has substantially identical functionality to the full length sequence itself. For example, when reference is made to a functional fragment of a bacteriophage genome, this indicates that the fragment, when contained in a bacteriophage, results in a bacteriophage according to the invention, i.e. a bacteriophage capable of lysing a P. acnes bacterium and incapable of lysing any bacterium which is not P. acnes , and which is incapable of sustaining lysogeny in a bacterium.
- the size of the functional fragment is at least 30% of the size of the full length sequence, more preferably at least 40% of the size, yet more preferably at least 50% of the size, yet more preferably at least 60%, 70%, 80%, 85%, 90% or 95% of the size.
- the bacteriophage has a genome which does not comprise one or more of the nucleotide sequences shown in SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.
- the properties of a bacteriophage according to the invention namely that the bacteriophage is capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium, may be associated with the absence of one or more of these sequences from the genome of the bacteriophage.
- the bacteriophage is isolated and is selected from those herein characterised as 103609, 103672 and 1894.
- the bacteriophage according to the first aspect of the invention may be modified to comprise a marker molecule.
- the term “marker molecule”, as used throughout this specification, is intended to include, but not be limited to, markers or tags such as biotin, a his-tag or a label recognisable by a binding partner such as an antibody, useable, for example, to isolate the bacteriophage. Markers suitable for use in affinity purification processes include glutathione-S-transferase (GST), protein A, ScFv and lectins.
- GST glutathione-S-transferase
- Other modifications of the bacteriophage may be made, e.g. for reducing phage antigenicity, including use of a PEG (polyethylene glycol) conjugate or a polysialic acid conjugate.
- Modifications may also include the addition of molecules which enhance the lethality of the phage to the bacterial host. Examples are given in Westwater C. et al. (2003) Antimicrob. Agents Chemotherapeutics 47: 1301-1307. Other suitable markers and modifications will be well known to the skilled person.
- the marker molecule may be incorporated at the DNA level or may be attached chemically at the phage surface.
- an isolated polynucleotide having the nucleotide sequence of the genome of a bacteriophage according to the first aspect of the invention.
- the polynucleotide may comprise the nucleotide sequence of any one of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or the complement thereof, or may comprise a functional fragment of the DNA sequence of any one of SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5; when a bacteriophage comprises a polynucleotide according to the second aspect of the invention, it has the properties of a bacteriophage according to the first aspect of the invention.
- the polynucleotide has sequence identity of at least 87% with the DNA sequence of SEQ ID NO:3, preferably sequence identity of at least 88%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence.
- the polynucleotide has sequence identity of at least 88% with the DNA sequence of SEQ ID NO:4, preferably sequence identity of at least 89%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence.
- the polynucleotide has sequence identity of at least 88% with the DNA sequence of SEQ ID NO:5, preferably sequence identity of at least 89%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence.
- the functional fragment may be selected from one or more of the Open Reading Frames (ORFs) shown in any of FIG. 2 , 3 or 4 , i.e. the ORFs within SEQ ID NO:3, 4, or 5 (respectively), the boundaries of which are defined in Table 5 below.
- the functional fragment may comprise a DNA sequence having sequence identity of at least 95% with any one of the DNA sequences selected from SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, preferably sequence identity of at least 96%, more preferably sequence identity of at least 97% with any one of those sequences, most preferably sequence identity of at least 98% or 99% with any one of those sequences.
- the functional fragment comprises the DNA sequence of SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.
- the functional fragment may comprise one or more of:
- the polynucleotide may comprise one or more of the Open Reading Frames shown in any of FIG. 2 , 3 or 4 .
- the polynucleotide has a nucleic acid sequence which does not comprise one or more of the sequences shown in SEQ ID NO:9.
- the properties of a bacteriophage containing a polynucleotide according to the second aspect of the invention namely that the bacteriophage is capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium, may be associated with the absence of one or more of these sequences from the polynucleotide according to the second aspect of the invention.
- the polynucleotide may further comprise a nucleotide sequence encoding a marker molecule.
- an isolated polypeptide having an amino acid sequence encoded by the polynucleotide according to the second aspect of the invention is provided.
- composition comprising at least one bacteriophage according to the first aspect of the invention and an adjuvant, carrier or vehicle.
- the composition is for use in the prevention or treatment of acne, or for use to improve the appearance of a mammal (preferably a human), the bacteriophage being present in an effective amount.
- treatment is intended to indicate the reduction or elimination of the occurrence of the symptoms of acne.
- symptoms include visible marks on the face such as papules (small raised red spots less than 5 mm in diameter), superficial pustules and deeper lesions (nodules and pustules larger than 5 mm in diameter). The deeper lesions can lead to scarring.
- the composition preferably comprises two or more different isolates of bacteriophage.
- Each of the two or more isolates of bacteriophage may be a bacteriophage according to the first aspect of the invention.
- the composition may comprise an isolated polynucleotide according to the second aspect of the invention or an isolated polypeptide according to the third aspect of the invention.
- the composition is for use in the prevention or treatment of acne, or for use to improve the appearance of a mammal (preferably a human)
- the isolated polynucleotide and/or isolated polypeptide is present in an effective amount.
- the composition may be in a form suitable for oral, intravenous or topical administration.
- the composition may be in a form suitable for oral administration and be a liquid, powder or tablet.
- the composition may be in a form suitable for intravenous administration and be a liquid, or a solid dissolvable in a liquid.
- the composition may be in a form suitable for topical administration and be in the form of a cream, solution, powder, spray, aerosol, capsule, solid or gel, or may be bonded to a solid surface.
- the composition may also form part of a face wash, soap, application stick, cosmetic or dressing.
- the bacteriophage, polynucleotide or polypeptide according to the invention contained in the composition may be within, or a part of, liposomes, capsules, carrier particles or, indeed, any other method of maintaining the bacteriophage, polynucleotide or polypeptide in a separate microenvironment within the composition.
- the bacteriophage, polynucleotide or polypeptide may be added directly to the composition, for example a bacteriophage may be added in a freeze-dried form.
- composition according to this aspect of the invention may further comprise at least one further agent selected from antibiotics, anti-comedonals, anti- P. acnes agents, anti-inflammatories and anti-seborrhoeics.
- the composition may be a pharmaceutical composition or a cosmetic composition.
- a method of preventing or treating acne comprising administering an effective amount of at least one bacteriophage according to the first aspect of the invention and/or of an isolated polynucleotide according to the second aspect of the invention and/or of an isolated polypeptide according to the third aspect of the invention and/or of a composition according to the fourth aspect of the invention to an individual in need of such prevention or treatment.
- a method of improving the appearance of an individual comprising administering to the individual an effective amount of a bacteriophage according to the first aspect of the invention and/or of an isolated polynucleotide according to the second aspect of the invention and/or of an isolated polypeptide according to the third aspect of the invention and/or of a composition according to the fourth aspect of the invention.
- the individual is a human individual.
- the method is a non-therapeutic cosmetic method.
- a method for isolating a bacteriophage capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium comprising:
- a method for identifying a bacteriophage which is capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium, comprising:
- step (b) at least three species of bacteria which are not P. acnes are exposed to the bacteriophage, more preferably at least four, at least five, at least 10, at least 20, at least 30, at least 40, or at least 50 different strains of bacteria.
- a bacteriophage isolated or identified using the method according to the seventh or eighth aspects of the invention is provided.
- a bacteriophage obtainable or identifiable by using a method according to the seventh or eighth aspects of the invention.
- FIGS. 1-8 Embodiments of the invention will now be described, by way of example only, with reference to the accompanying FIGS. 1-8 in which:
- FIG. 1 shows the arrangement of open reading frames (ORFs) in the PA6 genome, with putative functions of various ORFs indicated;
- FIG. 2 shows the arrangement of open reading frames (ORFs) in the 103609 genome, with putative functions of various ORFs indicated;
- FIG. 3 shows the arrangement of open reading frames (ORFs) in the 103672 genome, with putative functions of various ORFs indicated;
- FIG. 4 shows the arrangement of open reading frames (ORFs) in the 1894 genome, with putative functions of various ORFs indicated;
- FIG. 5 shows a graphical representation of DNA sequence alignment of phages 103672, 103609 and 1894;
- FIG. 6 shows a graphical representation of DNA sequence alignment of PA6 versus 103672, 103609 and 1894;
- FIG. 7 shows an alignment of a portion of the DNA sequences of bacteriophage strains 103609, 103672, 1894 and PA6;
- FIG. 8 shows an alignment of a further portion of the DNA sequences of bacteriophage strains 103609, 103672, 1894 and PA6
- TYG broth 1% (w/v) tryptone (Oxoid L42); 0.5% (w/v) yeast extract (Oxoid L21); 0.25% (w/v) glucose)
- Top agarose 0.7 g low-melting agarose added to 100 ml dH 2 O, heated to melt, cooled to 45° C., dispensed into 3 ml volumes and autoclaved.
- SM buffer (2.92 g NaCl; 1 g MgSO 4 .7H 2 O; 25 ml 1M Tris-Cl pH7.5; 0.05 g Gelatin; Dissolved in 500 ml dH 2 O and autoclaved.
- a multipoint inoculator can be used to apply phage spots to the surface of the plate.
- the bacteriophage strains were also tested against other species of bacteria, using the method outlined above but substituting other species for P. acnes .
- the species of bacteria tested were Propionibacterium granulosum, Propionibacterium avidum, Staphylococcus epidermidis and Corynebacterium bovis.
- Natural P. acnes numbers on the volunteer's back were known to be approximately 10 6 cfu cm ⁇ 2 (“cfu” denotes “colony forming units”).
- a scrub wash sample was taken from the back of the volunteer as set out in Method 2.1 above.
- a small aliquot was taken to determine the starting P. acnes count (10 5 cfu cm ⁇ 2 ).
- the rest of the sample was diluted 1:2 in 2 ⁇ TYG broth (1 ⁇ final TYG concentration) in order to grow the P. acnes . This was then further diluted in TYG to give 10-fold dilutions ranging from neat to 10 ⁇ 3 .
- each sample was diluted 10-fold from neat to 10 ⁇ 2 , filtered and treated with 10 mM ferrous ammonium sulphate (FAS), a compound which can inactivate free phage and which, in this context, is used to prevent carry-over of free (phage, which could give a false positive result.
- FAS ferrous ammonium sulphate
- Filters were plated on RCA+furazolidone plates (RCAF) and incubated anaerobically at 34° C. for 6 days. At the end of this period, the number of colony forming units for cm 3 was determined, by counting the number of colonies on the filter and using this figure to calculate the cfu in the original, undiluted, sample.
- Bacteriophage were subjected to lysogeny and super-infection immunity testing as follows. Phage were spotted onto lawns of P. acnes AT1 to produce plaques and these were incubated for periods of time sufficient to allow growth of bacteria within plaques, such bacteria having developed resistance to phage infection. Resistance can develop through changes on the surface of the bacterial cell (e.g. receptor) or internally (e.g. restriction enzymes). However, lysogeny confers resistance to related phages in a process called “superinfection immunity”. Repressor protein, expressed by the lysogen, prevents the integrated phage from synthesising the proteins necessary for reproduction. Repressor protein fulfils exactly the same function upon any homologous phage DNA coming into the cell, similarly preventing the production of phage. This can only happen if the incoming DNA is related to the lysogen such that the repressor can bind.
- Repressor protein expressed by the lysogen, prevents the integrated phage from synthesising the proteins necessary for
- phage were spotted onto the lawns to look for super-infection immunity to the same or other phage, an indication of lysogeny and/or resistance, since a plaque will form unless the bacteria are immune to infection by the particular phage.
- a plaque will form unless the bacteria are immune to infection by the particular phage.
- if they are immune to repeat infection by the same phage isolate this suggests the presence of that phage in lysogenic phase in the cell.
- this suggests the presence of the first phage in lysogenic phase in the cell. Phage which do not display such lysogenic qualities are considered to be suitable for use in embodiments of the invention.
- lytic phage phenotype such as entire or partial removal of the gene/site and functionally inactivating point mutation(s).
- a PCR-based method could detect the ligated cos site in cells which have been exposed to a bacteriophage of interest.
- Another method would be Southern blotting using labelled phage DNA to probe lysogens in the bacterial genome.
- Bacteriophage DNA was extracted and purified using the following method:
- ORF Open reading frames
- GeneMarkTM a family of gene prediction programs provided by Mark Borodovsky's Bioinformatics Group at the Georgia Institute of Technology, Atlanta, Ga.
- the ORF analysis tool there uses a heuristic approach to identifying possible genes using a computational method described in: Besemer J. and Borodovsky M. (1999) Nucl. Acids Res. 27: 3911-3920.
- the program can be found on the Internet at: http://opal.biology.gatech.edu/GeneMark/heuristic_hmm2.cgi
- Phage were screened for lysogenic activity as outlined in Method 4 above. Three of the broad host range phage listed in Table 3 above showed no evidence of lysogeny or resistance in these experiments, as outlined in Method 4 above, with results shown in Table 4. They were phages 1894, 103609 and 103672.
- ORF open reading frames
- FIG. 1 Analysis of open reading frames (ORF) within the PA6 genome and subsequent analysis of predicted protein sequences using the Blast database analysis tool identified various potential genes and highlighted possible functions (summary of analysis shown in FIG. 1 ).
- the 5′ end of the phage genome appears to host many of the structural genes which comprise the phage coat and tail. Notable among the remaining genes is a potential lysin (ORF 20) which shares homology with other lysins and an amidase protein within the P. acnes genome itself.
- the DNA sequence of this gene is shown in SEQ ID NO:2 and can be seen at nucleotides 15371-16233 of SEQ ID NO:1.
- ORF 20 in each case encodes a potential lysin.
- the DNA sequence for this gene is shown in SEQ ID NO: 6 (phage 103609, nucleotides 15442-16296 of SEQ ID NO: 3), SEQ ID NO:7 (phage 103672, nucleotides 15382-16245 of SEQ ID NO: 4) and SEQ ID NO:8 (phage 1894, nucleotides 15416-16273 of SEQ ID NO: 5).
- SEQ ID NO: 6 phage 103609, nucleotides 15442-16296 of SEQ ID NO: 3
- SEQ ID NO:7 phage 103672, nucleotides 15382-16245 of SEQ ID NO: 4
- SEQ ID NO:8 phage 1894, nucleotides 15416-16273 of SEQ ID NO: 5.
- Table 5 The boundaries for each ORF for each bacteriophage strain are shown in Table 5.
- FIG. 5 shows the outcome of a sequence homology analysis between 103609, 103672 and 1894, in which similarity level of 1.0 indicates 100% identity, with similarity falling according to the nature and number of differences between the three sequences. This analysis demonstrates that overall sequence identity between all of these three phage is 86.1%.
- FIG. 6 shows the results of a similar analysis between these three phage and PA6, a bacteriophage which does not show the desired characteristic of being incapable of sustaining lysogeny in a bacterium (see results Section III above).
- This analysis demonstrates that overall sequence identity between all of these four phage is 80.1%.
- Overall sequence identity between 1894 and PA6 is 87.4%, between 103609 and PA6 is 86.8% and between 103672 and PA6 is 87.3%.
- FIG. 6 clearly shows that there are two regions of low or zero % sequence identity when the DNA sequences of the three phage 103609, 103672 and 1894 are compared to that of PA6.
- FIGS. 7 and 8 show that this is the result of the presence of nucleotide sequences in PA6 which are not present in any of the other three phage.
- nucleotides 19804-10843 of PA6 are shown as SEQ ID NO: 9; nucleotides 19876-19901 of PA6 are shown as SEQ ID NO:10; nucleotides 19913-19969 of PA6 are shown as SEQ ID NO:11; nucleotides 19979-20054 of PA6 are shown as SEQ ID NO:12; and nucleotides 26242-26620 of PA6 are shown as SEQ ID NO:13.
- Bacteriophage 103672 was tested against P. acnes bacteria immediately after isolation of the bacteria from a volunteer's skin, as outlined in Method 3.4 above. The results are as shown in Table 7:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
There is provided a bacteriophage capable of lysing a P. acnes bacterium and incapable of lysing a bacterium which is not P. acnes, and which is incapable of sustaining lysogeny in a bacterium. There is also provided a pharmaceutical composition comprising such a bacteriophage.
Description
- The invention relates to bacteriophage and their uses. In particular, though not exclusively, it relates to their use in compositions for the treatment of acne.
- Acne vulgaris is one of the most common diseases of the skin and in cases of extreme disfigurement can sometimes have severe consequences for the personality development of young people with ensuing social and economic problems. Adolescents suffering from acne show higher levels of anxiety, greater social inhibition and increased aggression compared to non-acne individuals. Amongst skin diseases, acne is the second highest cause of suicides.
- Acne is an exclusively human disease and a unique condition of human sebaceous follicles of the face, chest and back. Spontaneous regression is common, taking about 15 years to complete. However, in about 5 percent of cases, acne persists beyond the age of 25 years and extends into the fourth and fifth decades of life. The earlier the symptoms start, the more severe is the course of the disease. The prevalence of the disease does not reflect any preference for male or female but usually the course is more severe in males.
- The onset of the disease in an individual coincides with entry into puberty and is associated with an androgen-driven rise in sebum excretion rate and an increased colonisation of the sebaceous follicles with Propionibacterium acnes (P. acnes). Recent data indicates that the initiation of individual lesions is primarily inflammatory rather than via keratinocyte hyperproliferation.
- Contrary to popular opinion, hygiene and diet have little or no effect on the aetiology of acne. Acne can be exacerbated by external factors such as friction (acne mechanica) (Shalita A R (1983) Cosmetics and Toiletries 98: 57-60) and pore-clogging cosmetics (acne cosmetica) (Mills O. H. & Kilgman A. M. (1988) Dermatol. Clin. 1: 365-370). The bacterium P. acnes is an inhabitant of the human skin and forms a major part of the natural skin flora. There is a wealth of circumstantial evidence implicating P. acnes as a major factor in the disease: increased colonisation of the skin by P. acnes is associated with the onset of the disease; patients with severe acne are significantly more sensitised to P. acnes than normal individuals; the overall immunological status of patients is elevated compared to acne-free individuals of the same age; successful antibiotic treatment reduces the density of P. acnes on the skin; and antibiotic therapeutic failure is associated with the presence of antibiotic resistant P. acnes on the skin of the patient.
- Current treatments for acne focus on various factors contributing to the disease. In summary, anti-comedonal treatments include retinoids and azelaic acid (topical treatments) and isotretinoin (oral treatments); anti-P. acnes treatments include benzoyl peroxide, azelaic acid, erythromycin, tetracycline and clindamycin (topical treatments) and tetracycline, erythromycin, minocycline and trimethoprim (oral treatments); anti-inflammatory treatments include tetracycline, erythromycin, clindamycin and nicotinamide (topical treatments) and tetracycline, minocycline, trimethoprim and isotretinoin (oral treatments); and anti-seborrhoeic treatments include spironolactone (topical treatments) and Dianette™ and isotretinoin (oral treatments).
- The more common mild and moderate cases of acne are treated with antibiotics, usually topically. There are increasing concerns emerging over the use of antibiotics for acne, where treatments last for long periods of time, up to 2-3 years in some cases. The concerns are two fold. First, the emergence of antibiotic resistant P. acnes world-wide with the consequence of reducing their efficacy for acne therapy. Second and possibly more importantly, there is the selection of an increasing pool of antibiotic resistant genes in the commensal microflora, mainly coagulase-negative staphylococci and corynebacteria, on patients' skin. These resistance genes may be horizontally transferred to related species, e.g. Staphylococcus aureus, which is a major opportunistic pathogen in the hospital and community environments. Therefore all efforts are required to restrict the use of antibiotics over extended treatment periods as used in the treatment of acne. Obtaining licences to market antibiotic therapies for acne is becoming especially difficult.
- Side effects from these treatments are commonplace. Mild irritant dermatitis is associated with virtually all topical therapies (Cunliffe W. J., (2001) Pharmaceut. J. 267 749-752). Oral courses of antibiotics have side effects regardless of the condition for which they are prescribed and these often result from their lack of specificity, unbalancing (in due course) much of the bacterial flora in many sites in the body. This leaves room for resistant flora to flourish, resulting in, for example, vaginal candidiasis in women. Retinoid treatment has many side effects: it is a teratogen; causes cheilitis, facial dermatitis and conjunctivitis; leads to secondary skin infections; and has been associated with mood swings and depression.
- Therefore, there is a need to develop new approaches for acne therapy which specifically target P. acnes.
- The idea of employing bacteriophage (naturally occurring bacterial viruses) for the treatment or prevention of bacterial diseases was realised relatively soon after the discovery of phage (the words “bacteriophage” and “phage” are used interchangeably throughout this specification) by Felix d'Herelle in 1917. The fact that bacteriophage can specifically infect a bacterial host and rapidly kill it suggested to d'Herelle that this was potentially a very effective way of controlling bacterial infection in man (for review, see “Felix d'Herelle and the Origins of Molecular Biology” William C. Summers (Yale University Press, ISBN 0-300-07127-2)). This potential was never fully realised because of the advent of the antibiotic era, but phage therapy has been pursued since then, in many cases successfully, in former states of the USSR and Eastern Europe.
- The emergence of drug resistance and the difficulty in developing novel antibiotics and vaccines has highlighted a growing need to find alternative methods of treatment.
- WO03/080823 discloses a method for generating candidate bacteriophage for use in therapy by mutating temperate bacteriophage and producing a cocktail of phages. This disclosure specifically selects lysogenic phage, observing that for some bacteria they are more numerous and, therefore, easier to isolate than lytic phage. The phage then have to be mutated to produce lytic vir mutants, in order to avoid the problems associated with lysogenic phage as a therapy, as discussed further below. Treatment of P. acnes is mentioned.
- EP0414304 relates to the use of bacteriophage to kill bacteria, including P. acnes. There is no disclosure of a bacteriophage capable of lysing multiple strains of P. acnes bacteria and yet which is incapable of lysing a bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium.
- Jong et al (Med. Microbiol. Immunol. 161 (1975) 263-271) describes isolation of P. acnes phage. The paper focuses on the classification of the phage and does not disclose a bacteriophage capable of lysing multiple strains of P. acnes bacteria and yet which is incapable of lysing a bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium.
- Puhvel & Reisner (Amer. Soc. Microbiol. 72 (1972) V201) is an abstract relating to the generation of lysogenic phage-resistant strains of P. acnes.
- WO01/51066 relates to the use of bacteriophage to reduce risk of infection or sepsis, particularly in immunocompromised patients. The disclosed methodology aims to achieve the numerical reduction or elimination of various members of the body's natural bacterial flora, in order to reduce the chance of them causing disease in immunocompromised patients. This is specifically risk reduction rather than cure and is concerned in particular with infections which complicate conditions such as certain cancers, AIDS and cystic fibrosis and which complicate the condition of transplant patients. No mention is made of treatment of P. acnes.
- U.S. Pat. No. 6,121,036 relates to a purified, host specific, non-toxic, wide host range bacteriophage preparation containing at least two phage. The document describes some of the features of an effective phage therapy—that it should be safe, have broad host range and kill a large proportion of bacteria strains—and indicates that such a preparation of appropriate phage could be used to treat P. acnes infections. However, no disclosure is made about which phage are suitable for this purpose or that such safe, lytic, broad host range phage exist for P. acnes.
- WO02/07742 purports to disclose a method for potentiating a wider host range for a phage by cloning tail protein-encoding genes from another phage with different host specificity. The document indicates that wide specificity is desirable from a phage therapy point of view but, rather than selecting from naturally occurring phage variants, describes the synthetic construction of a hybrid bacteriophage with dual tail fibre types, therefore having corresponding dual host specificity. This specificity is hypothetically extended to apply the invention in the engineering of a phage which can infect not only different species strains but different bacteria within a species and even within different genera. However, there is no evidence for this potential beyond results showing that a hybrid phage had been created having the ability to infect two different strains of Escherichia coli. The application of a suitably modified phage for gene therapy in humans is also contemplated. Specific phage, modified or unmodified, for the treatment of acne are not disclosed. There is no mention of a P. acnes bacteriophage with a single host species specificity but with multiple strain specificity.
- US2005/0032036 describes a method for sorting through a phage collection and determining the composition of a phage cocktail in order to optimise broad host range infection and lysis, particularly in reference to Pseudomonas and Staphylococcus strains. No disclosures are made in relation to the field of acne phage therapy.
- WO2005/009451 relates in particular to the use of bacteriophage as a part of a combination therapy with traditional, chemical antibiotics, particularly in the treatment of Pseudomonas aeruginosa infections and particularly in the treatment of bacteria within biofilms. It describes the difficulty in finding phage with sufficiently broad host specificity to be of therapeutic value for treatment of any given infection and advocates the use of multiple bacteriophage types for therapy, whether simultaneously, separately or sequentially. It also indicates that greater virulence in a phage can be induced artificially by genetic manipulation methods to produce phage with broader specificity or greater infection potential. There is no mention of P. acnes, which is not characterised by biofilm formation.
- US2004/0241825 discloses several methods for genetically labelling bacteriophage (with a non-functional stretch of DNA that can be detected by, for example, PCR, enabling identification of the phage), identifying non-cross reacting bacteriophage (a multi-step process to isolate phage against the target host and, from these, isolating bacteriophage which do not infect more than 5% of non-pathogenic, non-target hosts) and, finally, a method for selecting phage that are resistant to genetic modification by host bacteria (which involves infecting bacteria with a sample of bacteriophage, isolating progeny phage and comparing the restriction digest patterns of the original bacteriophage and the progeny to identify any differences that would be indicative of genetic modification). Implicit in this disclosure is the difficulty in identifying suitable candidate bacteriophage for use in a therapy. The application of this methodology to P. acnes is not described:
- Several conference presentations by the research group of Michael Davis at Central Connecticut State University have outlined plans to identify lytic phage having broad host range specificity (Vieira T. and Davis M. A. (1999) Viruses as Therapeutic Agents for Treating Bacterial Infections. Poster presentation on Apr. 24, 1999 at the 53rd Annual Eastern Colleges Science Conference, Sacred Heart University, Fairfield Conn.; Jedrzkiewicz B. and Davis M. A. (2000) Combating the Antibiotic Resistance Crisis: Therapeutic Use of Bacteriophages (Viruses) for Treating Acne, A Bacterial Disease. Poster presentation on Apr. 1, 2000 at the 54th Annual Eastern Colleges Science Conference, Wagner College, Staten Island N.Y.; Hany C. et al., (2001) The Use of Bacteriophage to Treat Acne, A Bacterial Disease. Poster presentation on Mar. 31, 2001 at the 55th Annual Eastern Colleges Science Conference, Wilkes University, Wilkes-Barre Pa.; Armack S. et al. (2002) Bacteriophage Therapy For The Treatment Of The Bacterial Disease Acne. Poster presentation on Apr. 27, 2002 at the 56th Annual Eastern Colleges Science Conference, Niagara University, Niagara N.Y.; Arminti K. et al. (2003) Bacteriophage Therapy For The Disease Acne: Identification And Purification Of Candidate Bacteriophage. Poster presentation on Apr. 12, 2003 at the 57th Annual Eastern Colleges Science Conference, Ithaca College, Ithaca N.Y.; Geronimo J. et al (2004) Bacteriophage Therapy For the Skin Disease Acne. Poster presentation on Apr. 2, 2004 at the 58th Annual Eastern Colleges Science Conference, Manhattan College, Riverdale N.Y.). No disclosures have been made in relation to the specific properties of such phage or to specific phage isolates.
- According to a first aspect of the invention there is provided a bacteriophage capable of lysing a P. acnes bacterium and incapable of lysing any bacterium which is not P. acnes, and which is incapable of sustaining lysogeny in a bacterium.
- Such a phage has the ability to infect a wide range of bacterial strains within a species but with absolute species specificity. This is one of the most important and usually unachievable aims in the development of an effective phage therapy. In addition, a bacteriophage according to the invention is purely lytic, i.e. incapable of entering the lysogenic phase of the bacteriophage life cycle, a quiescent stage which is undesirable in the creation of an effective therapy and is also unacceptable from a regulatory point of view.
- Advantageously, such a bacteriophage can be used in the treatment of acne. No side effects have been reported or are expected in the use of phage therapy, whether delivered systemically, orally or topically. The bacteriophage is specific to P. acnes and therefore leaves other members of the skin flora unaffected, reducing the opportunity for the overgrowth of potentially harmful flora. The protective nature of the normal resident microflora is therefore maintained. The specificity of a phage therapy approach to treatment of acne also eliminates the possibility of drug resistance emerging in other members of the microflora: other antibacterial treatments offer a broad brush stroke approach to eliminating bacteria and therefore, under the appropriate conditions, provide an opportunity for developing drug resistance not only in P. acnes but in other important commensals with pathogenic potential, e.g. Staphylococcus aureus. A further advantage of bacteriophage treatment is that it is self regulating: as the population of host P. acnes cells reduces, so will the bacteriophage numbers. In addition, such a bacteriophage can be used as a general prophylactic measure; the use of antibiotics in unprescribed cosmetic products (such as face washes, etc) is undesirable for many reasons relating to safety and the issue of antibiotic resistance. In fact there are strong arguments for limiting the use of antibiotics to reduce the incidence of resistance. Specificity of the bacteriophage means that it is suitable for widespread use in these situations and could be employed as part of a general hygiene routine for the prevention of acne. In addition, the use of the bacteriophage may be effective even against bacterial strains which have become resistant to antibiotics.
- As mentioned above, the use of a bacteriophage which can lyse P. acnes but is incapable of sustaining lysogeny has the advantage that the bacteriophage cannot lie dormant within a bacterium, but must lyse the bacterium and hence kill it.
- Preferably, the bacteriophage lacks the ability to express at least one gene necessary for sustaining lysogeny. The term “lacks the ability to express” is intended to indicate that the bacteriophage lacks the ability to produce a fully functional protein product necessary to sustain lysogeny, for example, as the result of one or more point mutations or full or partial deletions of the genome. More preferably, the phage has a genome which lacks all or part of at least one gene necessary for sustaining lysogeny. Alternatively or additionally, the phage may comprise defects (e.g. mutations, insertions or deletions) in the genome in non-coding regions which may, nonetheless, affect the ability of the phage to sustain lysogeny, for example defects in the genome integration site(s) (e.g. the /att/ site) or in the repressor binding site. The phage is preferably naturally occurring and isolated, with the added advantage that artificial mutations need not be introduced into the bacteriophage. Such mutations, whilst not ruled out, could have potentially unknown results which could be harmful to the individual to whom the bacteriophage is administered. If the phage contains artificial mutations, or is otherwise non-naturally occurring, it is still preferred that the phage is obtained in an isolated state.
- In a preferred embodiment, the bacteriophage according to this aspect of the invention is capable of lysing a plurality of strains of the P. acnes bacterium. For example, the bacteriophage according to this aspect of the invention may be capable of lysing 5 strains of the P. acnes bacterium, preferably at least 10 strains, more preferably at least 16 strains, or at least 17 strains, or at least 18 strains, or at least 19 strains, or at least 20 strains. Most preferably, the bacteriophage is capable of lysing at least 21 strains.
- Preferably, the bacteriophage according to this aspect of the invention is isolated and selected from those phage characterised hereinafter as: 103609; 103672; and 1894.
- The following isolates of bacteriophage have been deposited under the terms of the Budapest Treaty at The National Collection of Industrial, Marine and Food Bacteria (NCIMB), Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA, United Kingdom, under the following accession numbers: Accession no. NCIMB 41332 (isolate PA6); Accession no. NCIMB 41334 (isolate 1874); Accession no. NCIMB 41333 (isolate 1878); Accession no. NCIMB 41335 (isolate 1905); Accession no. NCIMB 41349 (isolate 1894); Accession no. NCIMB 41350 (isolate 103609); Accession no. NCIMB 41351 (isolate 103672). The host bacteria, P. acnes, AT1 was also deposited as NCIMB 41336.
- The bacteriophage may have a genome which comprises the DNA sequence of SEQ ID NO:3, or a genome having sequence identity of at least 87% with the DNA sequence of SEQ ID NO:3, more preferably sequence identity of at least 88% with that sequence, yet more preferably sequence identity of at least 90% with that sequence, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence. Alternatively or in addition, the bacteriophage may have a genome comprising a functional fragment of the DNA sequence of SEQ ID NO:3. For example, the functional fragment may be selected from within the Open Reading Frames shown in
FIG. 2 . Alternatively, the functional fragment may comprise a DNA sequence having sequence identity of at least 95% with the DNA sequence ofFIG. 6 , preferably sequence identity of at least 96%, more preferably sequence identity of at least 97% with that sequence, most preferably sequence identity of at least 98% or 99% with that sequence. In a preferred embodiment, the functional fragment comprises the DNA sequence ofFIG. 6 . - Alternatively, the bacteriophage may have a genome which comprises the DNA sequence of SEQ ID NO:4, or a genome having sequence identity of at least 88% with the DNA sequence of SEQ ID NO:4, more preferably sequence identity of at least 89% with that sequence, yet more preferably sequence identity of at least 90% with that sequence, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence. Alternatively or in addition, the bacteriophage may have a genome comprising a functional fragment of the DNA sequence of SEQ ID NO:4. For example, the functional fragment may be selected from within the Open Reading Frames shown in
FIG. 3 . Alternatively, the functional fragment may comprise a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:7, preferably sequence identity of at least 96%, more preferably sequence identity of at least 97% with that sequence, most preferably sequence identity of at least 98% or 99% with that sequence. In a preferred embodiment, the functional fragment comprises the DNA sequence of SEQ ID NO:7. - In a further alternative, the bacteriophage may have a genome which comprises the DNA sequence of SEQ ID NO:5, or a genome having sequence identity of at least 88% with the DNA sequence of SEQ ID NO:5, more preferably sequence identity of at least 89% with that sequence, yet more preferably sequence identity of at least 90% with that sequence, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence. Alternatively or in addition, the bacteriophage may have a genome comprising a functional fragment of the DNA sequence of SEQ ID NO:5. For example, the functional fragment may be selected from within the Open Reading Frames shown in
FIG. 4 . Alternatively, the functional fragment may comprise a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:8, preferably sequence identity of at least 96%, more preferably sequence identity of at least 97% with that sequence, most preferably sequence identity of at least 98% or 99% with that sequence. In a preferred embodiment, the functional fragment comprises the DNA sequence of SEQ ID NO:8. - Alternatively or additionally, the functional fragment may comprise the DNA sequence of one or more of:
- a DNA sequence having sequence identity of at least 63%, 70%, 80%, 90%, 95% or 99% with ORF1 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91%, 95% or 99% with ORF2 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91%, 95% or 99% with ORF3 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91%, 95% or 99% with ORF4 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 89%, 90%, 95% or 99% with ORF5 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 92%, 95% or 99% with ORF6 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 96%, 97%, 98% or 99% with ORF7 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 94%, 95% or 99% with ORF8 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 95%, 97%, 98% or 99% with ORF9 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91-%, 95% or 99% with ORF10 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 93%, 95% or 99% with ORF11 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 97%, 98% or 99% with ORF12 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 99% with ORF13 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91%, 95% or 99% with ORF14 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 93%, 95% or 99% with ORF15 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 94%, 95% or 99% with ORF16 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 97%, 98% or 99% with ORF17 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 67%, 70%, 80%, 90%, 95% or 99% with ORF18 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 80%, 90%, 95% or 99% with ORF19 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 88%, 90%, 95% or 99% with ORF20 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 86%, 90%, 95% or 99% with ORF21 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 97%, 98% or 99% with ORF22 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 98% or 99% with ORF23 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 93%, 95% or 99% with ORF24 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 87%, 90%, 95% or 99% with ORF25 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 63%, 70%, 80%, 90%, 95% or 99% with ORF26 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 80%, 90%, 95% or 99% with ORF27 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 78%, 80%, 90%, 95% or 99% with ORF28 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 66%, 70%, 80%, 90%, 95% or 99% with ORF29 of SEQ ID NO:3, 4 or 5; and/or
a DNA sequence having sequence identity of at least 87%, 90%, 95% or 99% with ORF30 of SEQ ID NO:3, 4 or 5. - Preferably, the functional fragment comprises a DNA sequence which is conserved between all of SEQ ID NO:3, 4 and 5.
- The bacteriophage may have a genome having sequence identity of at least 88% with the genome of the bacteriophage deposited under Accession No. NCIMB 41349, preferably sequence identity of at least 89%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99%.
- The bacteriophage may have a genome having sequence identity of at least 87% with the genome of the bacteriophage deposited under Accession No. NCIMB 41350, preferably sequence identity of at least 88%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99%.
- The bacteriophage may have a genome having sequence identity of at least 88% with the genome of the bacteriophage deposited under Accession No. NCIMB 41351, preferably sequence identity of at least 89%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99%. The term “sequence identity”, as used throughout this specification, is calculated as the percentage of nucleotides present in the smaller of the two sequences to be compared that may also be found in the larger of the two sequences, the nucleotides preferably being arranged in the same order in both sequences. The skilled person would readily be able to determine the level of sequence identity between sequences, for example by use of the Blast analysis tool at http://www.ncbi.nlm.nih.gov/BLAST/, using the default parameter settings. Preferably, the length of the shorter of the two sequences being compared is at least 60% of the length of the longer of the two sequences, more preferably at least 70% of the length, yet more preferably at least 80% of the length and still more preferably at least 90%, 95%, 96% 97% 98% or 99% of the length. In a most preferred embodiment, the sequences to be compared are identical in length.
- The term “functional fragment”, as used throughout this specification, indicates a portion of the full length sequence which has substantially identical functionality to the full length sequence itself. For example, when reference is made to a functional fragment of a bacteriophage genome, this indicates that the fragment, when contained in a bacteriophage, results in a bacteriophage according to the invention, i.e. a bacteriophage capable of lysing a P. acnes bacterium and incapable of lysing any bacterium which is not P. acnes, and which is incapable of sustaining lysogeny in a bacterium. Preferably, the size of the functional fragment is at least 30% of the size of the full length sequence, more preferably at least 40% of the size, yet more preferably at least 50% of the size, yet more preferably at least 60%, 70%, 80%, 85%, 90% or 95% of the size.
- In a preferred embodiment, the bacteriophage has a genome which does not comprise one or more of the nucleotide sequences shown in SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13. Without wishing to be bound by theory, it is considered that the properties of a bacteriophage according to the invention, namely that the bacteriophage is capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium, may be associated with the absence of one or more of these sequences from the genome of the bacteriophage.
- Preferably, the bacteriophage is isolated and is selected from those herein characterised as 103609, 103672 and 1894.
- The bacteriophage according to the first aspect of the invention may be modified to comprise a marker molecule. The term “marker molecule”, as used throughout this specification, is intended to include, but not be limited to, markers or tags such as biotin, a his-tag or a label recognisable by a binding partner such as an antibody, useable, for example, to isolate the bacteriophage. Markers suitable for use in affinity purification processes include glutathione-S-transferase (GST), protein A, ScFv and lectins. Other modifications of the bacteriophage may be made, e.g. for reducing phage antigenicity, including use of a PEG (polyethylene glycol) conjugate or a polysialic acid conjugate. Modifications may also include the addition of molecules which enhance the lethality of the phage to the bacterial host. Examples are given in Westwater C. et al. (2003) Antimicrob. Agents Chemotherapeutics 47: 1301-1307. Other suitable markers and modifications will be well known to the skilled person. The marker molecule may be incorporated at the DNA level or may be attached chemically at the phage surface.
- According to a second aspect of the invention, there is provided an isolated polynucleotide having the nucleotide sequence of the genome of a bacteriophage according to the first aspect of the invention. Alternatively or additionally, the polynucleotide may comprise the nucleotide sequence of any one of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or the complement thereof, or may comprise a functional fragment of the DNA sequence of any one of SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5; when a bacteriophage comprises a polynucleotide according to the second aspect of the invention, it has the properties of a bacteriophage according to the first aspect of the invention.
- Preferably, the polynucleotide has sequence identity of at least 87% with the DNA sequence of SEQ ID NO:3, preferably sequence identity of at least 88%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence.
- In an alternative preferred embodiment, the polynucleotide has sequence identity of at least 88% with the DNA sequence of SEQ ID NO:4, preferably sequence identity of at least 89%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence.
- In a further alternative preferred embodiment, the polynucleotide has sequence identity of at least 88% with the DNA sequence of SEQ ID NO:5, preferably sequence identity of at least 89%, more preferably sequence identity of at least 90%, most preferably sequence identity of at least 95%, 96%, 97%, 98% or 99% with that sequence.
- The functional fragment may be selected from one or more of the Open Reading Frames (ORFs) shown in any of
FIG. 2 , 3 or 4, i.e. the ORFs within SEQ ID NO:3, 4, or 5 (respectively), the boundaries of which are defined in Table 5 below. Alternatively, the functional fragment may comprise a DNA sequence having sequence identity of at least 95% with any one of the DNA sequences selected from SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, preferably sequence identity of at least 96%, more preferably sequence identity of at least 97% with any one of those sequences, most preferably sequence identity of at least 98% or 99% with any one of those sequences. In a more preferred embodiment, the functional fragment comprises the DNA sequence of SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8. - Alternatively or additionally, the functional fragment may comprise one or more of:
- a DNA sequence having sequence identity of at least 63%, 70%, 80%, 90%, 95% or 99% with ORF1 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91%, 95% or 99% with ORF2 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91%, 95% or 99% with ORF3 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91%, 95% or 99% with ORF4 of SEQ ID NO:3, 4 or 45;
a DNA sequence having sequence identity of at least 89%, 90%, 95% or 99% with ORF5 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 92%, 95% or 99% with ORF6 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 96%, 97%, 98% or 99% with ORF7 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 94%, 95% or 99% with ORF8 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 95%, 97%, 98% or 99% with ORF9 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91%, 95% or 99% with ORF10 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 93%, 95% or 99% with ORF11 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 97%, 98% or 99% with ORF12 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 99% with ORF13 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 91%, 95% or 99% with ORF14 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 93%, 95% or 99% with ORF15 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 94%, 95% or 99% with ORF16 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 97%, 98% or 99% with ORF17 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 67%, 70%, 80%, 90%, 95% or 99% with ORF18 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 80%, 90%, 95% or 99% with ORF19 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 88%, 90%, 95% or 99% with ORF20 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 86%, 90%, 95% or 99% with ORF21 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 97%, 98% or 99% with ORF22 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 98% or 99% with ORF23 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 93%, 95% or 99% with ORF24 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 87%, 90%, 95% or 99% with ORF25 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 63%, 70%, 80%, 90%, 95% or 99% with ORF26 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 80%, 90%, 95% or 99% with ORF27 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 78%, 80%, 90%, 95% or 99% with ORF28 of SEQ ID NO:3, 4 or 5;
a DNA sequence having sequence identity of at least 66%, 70%, 80%, 90%, 95% or 99% with ORF29 of SEQ ID NO:3, 4 or 5; and/or
a DNA sequence having sequence identity of at least 87%, 90%, 95% or 99% with ORF30 of SEQ ID NO:3, 4 or 5. - The polynucleotide may comprise one or more of the Open Reading Frames shown in any of
FIG. 2 , 3 or 4. - Preferably, the polynucleotide has a nucleic acid sequence which does not comprise one or more of the sequences shown in SEQ ID NO:9. SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13. Without wishing to be bound by theory, it is considered that the properties of a bacteriophage containing a polynucleotide according to the second aspect of the invention, namely that the bacteriophage is capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium, may be associated with the absence of one or more of these sequences from the polynucleotide according to the second aspect of the invention.
- The polynucleotide may further comprise a nucleotide sequence encoding a marker molecule.
- According to a third aspect of the invention there is provided an isolated polypeptide having an amino acid sequence encoded by the polynucleotide according to the second aspect of the invention.
- According to a fourth aspect of the invention, there is provided a composition comprising at least one bacteriophage according to the first aspect of the invention and an adjuvant, carrier or vehicle.
- Preferably, the composition is for use in the prevention or treatment of acne, or for use to improve the appearance of a mammal (preferably a human), the bacteriophage being present in an effective amount.
- The term “treatment” (and equivalent terms such as “treating”, “treat” etc), as used throughout this specification, is intended to indicate the reduction or elimination of the occurrence of the symptoms of acne. For example, symptoms include visible marks on the face such as papules (small raised red spots less than 5 mm in diameter), superficial pustules and deeper lesions (nodules and pustules larger than 5 mm in diameter). The deeper lesions can lead to scarring.
- The composition preferably comprises two or more different isolates of bacteriophage. Each of the two or more isolates of bacteriophage may be a bacteriophage according to the first aspect of the invention.
- Additionally or alternatively, the composition may comprise an isolated polynucleotide according to the second aspect of the invention or an isolated polypeptide according to the third aspect of the invention. Where the composition is for use in the prevention or treatment of acne, or for use to improve the appearance of a mammal (preferably a human), the isolated polynucleotide and/or isolated polypeptide is present in an effective amount.
- The composition may be in a form suitable for oral, intravenous or topical administration. For example, the composition may be in a form suitable for oral administration and be a liquid, powder or tablet. Alternatively, the composition may be in a form suitable for intravenous administration and be a liquid, or a solid dissolvable in a liquid. In a further alternative, the composition may be in a form suitable for topical administration and be in the form of a cream, solution, powder, spray, aerosol, capsule, solid or gel, or may be bonded to a solid surface. The composition may also form part of a face wash, soap, application stick, cosmetic or dressing.
- The bacteriophage, polynucleotide or polypeptide according to the invention contained in the composition may be within, or a part of, liposomes, capsules, carrier particles or, indeed, any other method of maintaining the bacteriophage, polynucleotide or polypeptide in a separate microenvironment within the composition. Alternatively, the bacteriophage, polynucleotide or polypeptide may be added directly to the composition, for example a bacteriophage may be added in a freeze-dried form.
- The composition according to this aspect of the invention may further comprise at least one further agent selected from antibiotics, anti-comedonals, anti-P. acnes agents, anti-inflammatories and anti-seborrhoeics.
- The composition may be a pharmaceutical composition or a cosmetic composition.
- According to a fifth aspect of the invention, there is provided a method of preventing or treating acne comprising administering an effective amount of at least one bacteriophage according to the first aspect of the invention and/or of an isolated polynucleotide according to the second aspect of the invention and/or of an isolated polypeptide according to the third aspect of the invention and/or of a composition according to the fourth aspect of the invention to an individual in need of such prevention or treatment.
- According to a sixth aspect of the invention, there is provided a method of improving the appearance of an individual, the method comprising administering to the individual an effective amount of a bacteriophage according to the first aspect of the invention and/or of an isolated polynucleotide according to the second aspect of the invention and/or of an isolated polypeptide according to the third aspect of the invention and/or of a composition according to the fourth aspect of the invention. Preferably, the individual is a human individual. The method is a non-therapeutic cosmetic method.
- According to a seventh aspect of the invention, there is provided a method for isolating a bacteriophage capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium, comprising:
-
- a) obtaining a sample of bacteria from a skin surface:
- b) isolating from the sample bacteriophage which lyse propionibacteria;
- c) isolating the bacteriophage to determine if it is capable of lysing at least one P. acnes strain;
- d) testing the bacteriophage to determine if it is capable of lysing non-P. acnes bacterial strains;
- e) testing the bacteriophage to determine whether it is capable of sustaining lysogeny in a P. acnes strain;
- f) detecting a bacteriophage which has been shown in steps (c), (d) and (e) to be capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes, and incapable of sustaining lysogeny in a bacterium.
- According to an eighth aspect of the invention, there is provided a method for identifying a bacteriophage which is capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium, comprising:
-
- a) exposing a P. acnes bacterium to the bacteriophage and determining that the bacterium is lysed;
- b) exposing at least one species of bacteria which is not P. acnes bacteria to the bacteriophage and determining that the bacteria are not lysed;
- c) determining that the bacteriophage is not capable of sustaining lysogeny in a bacteria.
- Preferably, in step (b), at least three species of bacteria which are not P. acnes are exposed to the bacteriophage, more preferably at least four, at least five, at least 10, at least 20, at least 30, at least 40, or at least 50 different strains of bacteria.
- According to a ninth aspect of the invention, there is provided a bacteriophage isolated or identified using the method according to the seventh or eighth aspects of the invention.
- According to a tenth aspect of the invention, there is provided a bacteriophage obtainable or identifiable by using a method according to the seventh or eighth aspects of the invention.
- Embodiments of the invention will now be described, by way of example only, with reference to the accompanying
FIGS. 1-8 in which: -
FIG. 1 shows the arrangement of open reading frames (ORFs) in the PA6 genome, with putative functions of various ORFs indicated; -
FIG. 2 shows the arrangement of open reading frames (ORFs) in the 103609 genome, with putative functions of various ORFs indicated; -
FIG. 3 shows the arrangement of open reading frames (ORFs) in the 103672 genome, with putative functions of various ORFs indicated; -
FIG. 4 shows the arrangement of open reading frames (ORFs) in the 1894 genome, with putative functions of various ORFs indicated; -
FIG. 5 shows a graphical representation of DNA sequence alignment ofphages -
FIG. 6 shows a graphical representation of DNA sequence alignment of PA6 versus 103672, 103609 and 1894; -
FIG. 7 shows an alignment of a portion of the DNA sequences of bacteriophage strains 103609, 103672, 1894 and PA6; and -
FIG. 8 shows an alignment of a further portion of the DNA sequences of bacteriophage strains 103609, 103672, 1894 and PA6 - Reinforced Clostridial Agar (RCA; Oxoid CM0151 (Oxoid Ltd., Basingstoke, UK))
- TYG broth (1% (w/v) tryptone (Oxoid L42); 0.5% (w/v) yeast extract (Oxoid L21); 0.25% (w/v) glucose)
- Top agarose (0.7 g low-melting agarose added to 100 ml dH2O, heated to melt, cooled to 45° C., dispensed into 3 ml volumes and autoclaved.)
- SM buffer (2.92 g NaCl; 1 g MgSO4.7H2O; 25 ml 1M Tris-Cl pH7.5; 0.05 g Gelatin; Dissolved in 500 ml dH2O and autoclaved.)
- The strains of P. acnes and phage isolates used in the screening were obtained from patients attending the Dermatology Department at the Leeds General Infirmary (except P. acnes NCTC737 and DSM16379). The method is based on that described in Williamson P. & Kligman A. M. (1965) J. Invest. Dermatol. 45: 498-503.
-
- a) Place a sterile metal ring onto the surface of the skin and press to ensure a good seal;
- b)
Pipette 1 ml wash fluid (75 mM phosphate buffer, pH7.9) into the ring; - c) Gently scrub the surface of the skin for 1 min with a sterile. Teflon rod;
- d) Remove the wash fluid to a sterile bottle and replace with another 1 ml of sterile wash fluid;
- e) Repeat scrubbing procedure then remove the fluid and pool with the first sample;
- f) Plate serial dilutions (or spiral plate) of the sample onto RCA containing 6 μg ml−1 furazolidone (which inhibits growth of staphylococci but not of propionibacteria) and incubate anaerobically for 7 days at 34° C.;
- g) Recover individual bacterial colonies or bacteriophage plaques (using method 2.2 described below) and propagate by restreak (bacteria) or the method described below (‘Preparation of phage stocks—lysate’) for bacteriophage plaque.
-
-
- a) Plate out phage-containing bacteria as described above and incubate for 24-48 h;
- b) Pick 2-3 plugs of agar from a single plaque into 1 ml SM buffer in a screw-top vial using a glass Pasteur pipette;
- c) Store at 4° C.
-
-
- a) Plate out phage-containing bacteria as described above and incubate for 24-48 h;
- b) Overlay plate with 5 ml SM buffer and leave for 1 h at room temperature with occasional swirling;
- c) Pipette buffer into a sterile tube (plastic universal or Falcon) then scrape top agarose off the plate into the tube;
- d) Centrifuge at >5000 rpm for 10 min at 4° C.;
- e) Remove supernatant and filter sterilise (0.2 μm filter);
- f) Aliquot and store at 4° C.
- 3.1 Plating of P. acnes Bacteriophage
-
- a) Melt top agarose in a 70° C. water bath then cool to 44° C.;
- b) Centrifuge cultures of P. acnes at 5000 rpm for 10 min in a bench-top centrifuge;
- c) Resuspend cells to an OD600 of 2.5 in SM buffer;
- d) Add 100 μl of P. acnes to an aliquot of phage (usually 5-10 μl) in a microcentrifuge tube, briefly mix and then incubate at 34° C. for 15 min;
- e) Gently pipette the P. acnes/phage mixture into 3 ml top agarose and invert to mix;
- f) Pour onto a dry RCA plate and swirl to cover surface;
- g) Allow to set and incubate anaerobically at 34° C. for 24-48 h.
3.2 P. acnes Bacteriophage Infectivity Assay - a) Melt top agarose in a 70° C. water bath then cool to 44° C.;
- b) Centrifuge cultures of P. acnes at 5000 rpm for 10 min in a bench-top centrifuge;
- c) Resuspend cells to an OD600 of 2.5 in SM buffer;
- d) Add 100 μl of P. acnes to 3 ml top agarose and shake to mix;
- e) Pour onto a dry RCA plate and swirl to cover surface;
- f) Allow agarose to set then dry plate again for 15-20 min;
- g)
Spot 5 μl of each phage onto the plate; - h) Allow spots to soak in and incubate anaerobically at 34° C. for 48 h.
- For high throughput screening of phage a multipoint inoculator can be used to apply phage spots to the surface of the plate.
- 3.3 Infectivity Assay of Bacteriophage Against Other Non-P. acnes Species
- The bacteriophage strains were also tested against other species of bacteria, using the method outlined above but substituting other species for P. acnes. The species of bacteria tested were Propionibacterium granulosum, Propionibacterium avidum, Staphylococcus epidermidis and Corynebacterium bovis.
- 3.4 Infectivity Assay of
Bacteriophage 103672 on P. acnes Immediately after Isolation from Skin of a Volunteer - Natural P. acnes numbers on the volunteer's back were known to be approximately 106 cfu cm−2 (“cfu” denotes “colony forming units”). A scrub wash sample was taken from the back of the volunteer as set out in Method 2.1 above. A small aliquot was taken to determine the starting P. acnes count (105 cfu cm−2). The rest of the sample was diluted 1:2 in 2×TYG broth (1× final TYG concentration) in order to grow the P. acnes. This was then further diluted in TYG to give 10-fold dilutions ranging from neat to 10−3. Two samples of each dilution were aliquoted,
phage 103672 added to one (106 pfu ml−1 final concentration, “pfu” denoting “plaque forming units”) at a ratio of 6:1 phage:cell and SM added to the other as a control. These were then incubated anaerobically at 34° C. for 48 h. - Following incubation, each sample was diluted 10-fold from neat to 10−2, filtered and treated with 10 mM ferrous ammonium sulphate (FAS), a compound which can inactivate free phage and which, in this context, is used to prevent carry-over of free (phage, which could give a false positive result. Filters were plated on RCA+furazolidone plates (RCAF) and incubated anaerobically at 34° C. for 6 days. At the end of this period, the number of colony forming units for cm3 was determined, by counting the number of colonies on the filter and using this figure to calculate the cfu in the original, undiluted, sample.
- Bacteriophage were subjected to lysogeny and super-infection immunity testing as follows. Phage were spotted onto lawns of P. acnes AT1 to produce plaques and these were incubated for periods of time sufficient to allow growth of bacteria within plaques, such bacteria having developed resistance to phage infection. Resistance can develop through changes on the surface of the bacterial cell (e.g. receptor) or internally (e.g. restriction enzymes). However, lysogeny confers resistance to related phages in a process called “superinfection immunity”. Repressor protein, expressed by the lysogen, prevents the integrated phage from synthesising the proteins necessary for reproduction. Repressor protein fulfils exactly the same function upon any homologous phage DNA coming into the cell, similarly preventing the production of phage. This can only happen if the incoming DNA is related to the lysogen such that the repressor can bind.
- The centres of the turbid plaques were picked and streaked out to obtain single colonies of bacteria apparently resistant to infection by the phage, which may or may not have been lysogenic. At this stage, there was no way of knowing which mechanism of resistance, discussed above, had been acquired. Single colonies were picked and grown in tryptone/yeast extract/glucose (TYG) broth before plating as lawns in top agarose on reinforced clostridial agar (RCA) plates. First, spontaneous plaque formation was identified, indicating phage lysogeny as the result of earlier infection with a lysogenic phage. Second, phage were spotted onto the lawns to look for super-infection immunity to the same or other phage, an indication of lysogeny and/or resistance, since a plaque will form unless the bacteria are immune to infection by the particular phage. As outlined above, if they are immune to repeat infection by the same phage isolate, this suggests the presence of that phage in lysogenic phase in the cell. Similarly, if they are immune to infection by another phage isolate, this (suggests the presence of the first phage in lysogenic phase in the cell. Phage which do not display such lysogenic qualities are considered to be suitable for use in embodiments of the invention.
- Alternative methods of identifying whether a phage can become lysogenic are PCR detection using primers specific to, for example, the phage repressor DNA, where a positive PCR result would indicate the presence of phage repressor DNA and, therefore, that the bacteriophage in question had the ability to become lysogenic. Absence of a repressor gene is one way of avoiding lysogeny, but other deletions which would convert a lysogenic phage into a lytic phage would include any that removes other parts of the integration machinery, i.e. phage-encoded integrase proteins and DNA sequences required for insertion into host DNA (att sites). Any sort of error which inactivates these genes or sites will achieve the desired lytic phage phenotype, such as entire or partial removal of the gene/site and functionally inactivating point mutation(s). Alternatively, a PCR-based method could detect the ligated cos site in cells which have been exposed to a bacteriophage of interest. Another method would be Southern blotting using labelled phage DNA to probe lysogens in the bacterial genome. These and other such methods are easily within the ability of the skilled person, who would clearly understand how to approach such methods in order to reliably identify whether a phage can become lysogenic and whether, therefore, it falls within the scope of the present invention.
- Bacteriophage DNA was extracted and purified using the following method:
-
- a) Prepare a plate lysate of the phage (10 ml)
- b) Add NaCl to 1 M and PEG8000 to 10% (w/v) and dissolve slowly
- c) Incubate on ice for 30 min to allow phage to precipitate
- d) Harvest phage by centrifuging at 10,000 g for 10 min at 4° C.
- e) Resuspend in 1 ml SM buffer
- f) Add an equal volume of chloroform and vortex for 30 sec
- g) Centrifuge at 3000 g for 15 min at 4° C.
- h) Remove the upper layer containing phage to a sterile tube
- i) Add proteinase K to 50 μg ml−1 and SDS to 0.5% (w/v) and incubate at 56° C. for 1 hour
- j) Cool, then extract twice with phenol:chloroform and once with chloroform
- k) Precipitate DNA with 2 volumes of ethanol
- l) Transfer DNA to 1 ml 70% (v/v) ethanol using a Pasteur pipette
- m) Recover DNA by centrifugation at 12,000 g for 2 min, discard supernatant and redissolve the DNA in TE buffer or dH2O
- Sequencing was carried out by Lark Technologies Inc. (Houston, Tex.). PA6, 103609, 103672 and 1894 DNA was prepared as above and then used to prepare a shotgun library from which clones were sequenced to derive the full genome sequence for each bacteriophage.
- Open reading frames (ORF) in several bacteriophage isolates were analysed using software available through GeneMark™, a family of gene prediction programs provided by Mark Borodovsky's Bioinformatics Group at the Georgia Institute of Technology, Atlanta, Ga. The ORF analysis tool there uses a heuristic approach to identifying possible genes using a computational method described in: Besemer J. and Borodovsky M. (1999) Nucl. Acids Res. 27: 3911-3920. The program can be found on the Internet at: http://opal.biology.gatech.edu/GeneMark/heuristic_hmm2.cgi
- Gene product functions were determined by database comparison using the Blast analysis tool at http://www.ncbi.nlm.nih.gov/BLAST/.
- I. Testing of Bacteriophage Against Stock P. acnes Strains
- A collection of 46 independent bacteriophage isolates were tested against a panel of 21P. acnes strains chosen for their diversity in age, origin and drug resistance profiles (listed in Table 1).
-
TABLE 1 List of strains used in bacteriophage host range screening tests. Strain number Bacterial isolate 1 P37 2 AT1 3 NCTC737 4 PF276 5 PF286 6 P506 7 CavillA 8 CavillB 9 AT4 10 AT5 11 101842c 12 101845a 13 101845b 14 101846c 15 101847a 16 101848 17 101849 18 101850a 19 101850b 20 101851a 21 DSM16379 - The ability of each bacteriophage to lyse each bacterial strain was tested to give an indication of the breadth of host specificity of each phage. The results in Table 2 show that, in general, all phages had broad specificity. Of these, 14 were able to infect all strains tested: PA6, 103609, 103625, 103629, 103664, 103672, 103715, 1869, 1874, 1878, 1894, 1905, 1909 and P37P.
-
TABLE 2 Summary of results from bacteriophage host range testing. Phage P. acnes strain Isolate 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 PA6 + + + + + + + + + + + + + + + + + + + + + 103205 − + + − + + + + + + + + + + − + + + + + 103600 − + + − + + + + + + + + + + + + + + + + 103601 − + + − + + + + + + + + + + + + + + + + 103609 + + + + + + + + + + + + + + + + + + + + + 103611 + + + + + + + + + + + + + + + + + + + + − 103614 + + + − + + + + + + + + + + − + + + + + 103625 + + + + + + + + + + + + + + + + + + + + + 103629 + + + + + + + + + + + + + + + + + + + + + 103657 − + + − + + + + − + + + + + + + + + + + 103664 + + + + + + + + + + + + + + + + + + + + + 103666 + + + + + + + + + + + + + + + + + + + + − 103671 + + + + + + + + + + + + + + + + + + + + − 103672 + + + + + + + + + + + + + + + + + + + + + 103683 + + + + + + + + + + + + + + + + + + + + − 103695 + + + + + + + + + + + + + + + + + + + + − 103698 − + + − + + + + − + + + + + − + + + + + 103704 + + + + + + + + + + + + + + + + + + + + − 103713 + + + + + + + + + + + + + + + + + + + + − 103715 + + + + + + + + + + + + + + + + + + + + + 138 − + + + + + + + + + + + + + + + + + + + 139 − + + − + + + + + + + + + + − + + + + + 140 − + + − + + + + − + + + + + − + + + + + 1869 + + + + + + + + + + + + + + + + + + + + + 1874 + + + + + + + + + + + + + + + + + + + + + 1877 − + + − + + + + + + + + + + − + + + + + 1878 + + + + + + + + + + + + + + + + + + + + + 1880 − + + − + + + + + + + + + + − + + + + + 1881 − + + − + + + + − + + + + + − + + + + + 1883 − + + − + + + + + + + + + + − + + + + + 1885 + + + + + + + + + + + + + + + + + + + + − 1888 − + + − + + + + + + + + + + − + + + + + 1894 + + + + + + + + + + + + + + + + + + + + + 1895 − + + + + + + + + + + + + + − + + + + + 1900 − + + − + + + + + + + + + + + + + + + + 1901 − + + − + + + + − + + + + + − + + + + + 1902 − + + − + + + + + + + + + + − + + + + + 1905 + + + + + + + + + + + + + + + + + + + + + 1909 + + + + + + + + + + + + + + + + + + + + + 1922 − + + − + + + + + + + + + + − + + + + + 1923 − + + − + + + + + + + + + + − + + + + + 1925 + + + + + + + + + + + + + + + + + + + + − 1928 − + + − + + + + + + + + + + − + + + + + 1929 − + + − + + + + + + + + + + − + + + + + P37P + + + + + + + + + + + + + + + + + + + + + “+” denotes a positive reaction where bacteriophage is able to infect the host after applying neat phage stock to a seeded lawn of host bacteria in agar overlay. “−” denotes a negative reaction where no infection was evident. - None of these strains showed an ability to infect the P. granulosum, P. avidum, S. epidermidis and C. bovis species tested.
- II. Testing of bacteriophage PA6, 103609, 103625, 103629, 103664, 103672, 103715, 1869, 1874, 1878, 1894, 1905, 1909 and P37P Against P. acnes Isolated from Volunteers' Skin
- The 14 strains, shown above to have broad specificity, were further tested against 31 additional P. acnes strains, isolated from the skin of volunteers. The bacteriophage all showed lytic activity against these additional strains, as shown in Table 3:
-
TABLE 3 Summary of results from bacteriophage host range testing. Phage isolate 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PA6 + + + + + + + + + + + + + + + + P37P + + + + + + + + + + + + + + + + 1869 + + + + + + + + + + + + + + + + 1874 + + + + + + + + + + + + + + + + 1878 + + + + + + + + + + + + + + + + 1894 + + + + + + + + + + + + + + + + 1905 + + + + + + + + + + + + + + + + 1909 + + + + + + + + + + + + + + + + 103609 + + + + + + + + + + + + + + + + 103625 + + + + + + + + + + + + + + + + 103629 + + + + + + + + + + + + + + + + 103664 + + + + + + + + + + + + + + + + 103672 + + + + + + + + + + + + + + + + 103715 + + + + + + + + + + + + + + + + Phage isolate 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 PA6 + + + + + + + + + + + + + + + P37P + + + + + + + + + + + + + + + 1869 + + + + + + + + + + + + + + + 1874 + + + + + + + + + + + + + + + 1878 + + + + + + + + + + + + + + + 1894 + + + + + + + + + + + + + + + 1905 + + + + + + + + + + + + + + + 1909 + + + + + + + + + + + + + + + 103609 + + + + + + + + + + + + + + + 103625 + + + + + + + + + + + + + + + 103629 + + + + + + + + + + + + + + + 103664 + + + + + + + + + + + + + + + 103672 + + + + + + + + + + + + + + + 103715 + + + + + + + + + + + + + + + “+” denotes a positive reaction where bacteriophage is able to infect the host after applying neat phage stock to a seeded lawn of host bacteria in agar overlay. “−” denotes a negative reaction where no infection was evident.
III. Identification of Non-Lysogenic P. acnes Bacteriophage - Phage were screened for lysogenic activity as outlined in
Method 4 above. Three of the broad host range phage listed in Table 3 above showed no evidence of lysogeny or resistance in these experiments, as outlined inMethod 4 above, with results shown in Table 4. They werephages -
TABLE 4 Data from repeated attempts to demonstrate lysogenic potential in phage. Phage infections (left column) of P. acnes strain AT1 were incubated for prolonged periods such that growth was visible within plaques. These emergent bacteria were sampled and tested for their susceptibility to infection with homologous or heterologous phage (top row). Potential Phage spotted onto lawn - plaque (infection) present? Lysogen PA6 P37P 1869 1874 1878 1894 1905 1909 103609 103625 103629 103664 103672 103715 PA6 N N N N N Y N Y Y N N N Y N P37P N N N N N Y N Y Y N N N Y N 1869 Y Y Y Y Y Y Y Y Y Y Y Y Y Y 1874 Y Y N Y Y Y Y Y Y Y Y Y Y Y 1878 N N Y N N Y N Y Y N N N Y N 1894 Y Y Y Y Y Y Y Y Y Y Y Y Y Y 1905 N N N N N Y N Y Y N N N Y N 1909 N N N N N Y N N Y N N N Y N 103609 Y Y Y Y Y Y Y Y Y Y Y Y Y Y 103625 N Y N N Y Y Y Y Y Y Y Y Y N 103629 N Y N N N Y N N Y N N N Y N 103664 N Y N N N Y N Y Y N N Y Y N 103672 Y Y Y Y Y Y Y Y Y Y Y Y Y Y 103715 N Y N N N Y Y Y Y N Y Y Y N ‘N’ indicates resistance and therefore demonstration of lysogenic activity. Three strains - The genome for each of bacteriophages PA6, 103609, 103672 and 1894 was sequenced as outlined in
Method 5 above. The sequences for each are shown in SEQ ID NO:1 (PA6), SEQ ID NO:3 (103609), SEQ ID NO:4 (103672) and SEQ ID NO:5 (1894). - Analysis of open reading frames (ORF) within the PA6 genome and subsequent analysis of predicted protein sequences using the Blast database analysis tool identified various potential genes and highlighted possible functions (summary of analysis shown in
FIG. 1 ). The 5′ end of the phage genome appears to host many of the structural genes which comprise the phage coat and tail. Notable among the remaining genes is a potential lysin (ORF 20) which shares homology with other lysins and an amidase protein within the P. acnes genome itself. The DNA sequence of this gene is shown in SEQ ID NO:2 and can be seen at nucleotides 15371-16233 of SEQ ID NO:1. - A similar analysis was carried out for the genomes of 103609, 103672 and 1894, with the summary shown in
FIG. 2 (103609),FIG. 3 (103672),FIG. 4 (1894) and Table 5. Again,ORF 20 in each case encodes a potential lysin. The DNA sequence for this gene is shown in SEQ ID NO: 6 (phage 103609, nucleotides 15442-16296 of SEQ ID NO: 3), SEQ ID NO:7 (phage 103672, nucleotides 15382-16245 of SEQ ID NO: 4) and SEQ ID NO:8 (phage 1894, nucleotides 15416-16273 of SEQ ID NO: 5). The boundaries for each ORF for each bacteriophage strain are shown in Table 5. No repressor protein is obvious from sequence homology analysis in these phage strains and this is an indication that these are purely lytic phage, unable to sustain lysogeny, as supported by the results shown in Table 4. Therefore, this confirms that these phage strains are ideal in this respect as candidates for phage therapy. -
TABLE 5 ORF boundaries for phage 103609, 103672 and 1894 1894 ORFs (30 total) 103609 ORFs (32 total) 103672 ORFs (32 total) ORF 1 Start: 53 End: 361 ORF 1 Start: 145 End: 363 ORF 1 Start: 113 End: 361 ORF 2 Start: 361 End: 1872 ORF 2 Start: 363 End: 1874 ORF 2 Start: 361 End: 1872 ORF 3 Start: 1869 End: 3194 ORF 3 Start: 1871 End: 3196 ORF 3 Start: 1869 End: 3194 ORF 4 Start: 3201 End: 3956 ORF 4 Start: 3203 End: 3958 ORF 4 Start: 3198 End: 3953 ORF 5 Start: 4067 End: 4621 ORF 5 Start: 4069 End: 4629 ORF 5 Start: 4057 End: 4611 ORF 6 Start: 4628 End: 5575 ORF 6 Start: 4636 End: 5583 ORF 6 Start: 4618 End: 5565 ORF 7 Start: 5620 End: 6081 ORF 7 Start: 5627 End: 6088 ORF 7 Start: 5613 End: 6074 ORF 8 Start: 6083 End: 6430 ORF 8 Start: 6090 End: 6437 ORF 8 Start: 6076 End: 6422 ORF 9 Start: 6437 End: 6727 ORF 9 Start: 6444 End: 6734 ORF 9 Start: 6430 End: 6720 ORF 10 Start: 6724 End: 7095 ORF 10 Start: 6731 End: 7102 ORF 10 Start: 6717 End: 7087 ORF 11 Start: 7147 End: 7776 ORF 11 Start: 7154 End: 7795 ORF 11 Start: 7140 End: 7769 ORF 12 Start: 7803 End: 8099 ORF 12 Start: 7824 End: 8120 ORF 12 Start: 7797 End: 8093 ORF 13 Start: 8198 End: 8485 ORF 13 Start: 8219 End: 8506 ORF 13 Start: 8192 End: 8479 ORF 14 Start: 8493 End: 11258 ORF 14 Start: 8514 End: 11279 ORF 14 Start: 8487 End: 11252 ORF 15 Start: 11274 End: 12215 ORF 15 Start: 11295 End: 12236 ORF 15 Start: 11270 End: 12211 ORF 16 Start: 12223 End: 13380 ORF 16 Start: 12244 End: 13401 ORF 16 Start: 12219 End: 13376 ORF 17 Start: 13430 End: 14218 ORF 17 Start: 13451 End: 14239 ORF 17 Start: 13425 End: 14213 ORF 18 Start: 14299 End: 14538 ORF 18 Start: 14296 End: 14559 ORF 18 Start: 14259 End: 14522 ORF 19 Start: 14541 End: 15374 ORF 19 Start: 14563 End: 15387 ORF 19 Start: 14525 End: 15340 ORF 20 Start: 15416 End: 16273 ORF 20 Start: 15442 End: 16296 ORF 20 Start: 15382 End: 16245 ORF 21 Start: 16286 End: 16684 ORF 21 Start: 16309 End: 16707 ORF 21 Start: 16258 End: 16656 ORF 22 Start: 19047 End: 19103 ORF 22 Start: 20662 End: 20766 ORF 22 Start: 18710 End: 18955 ORF 23 Start: 23248 End: 23391 ORF 23 Start: 20767 End: 20919 ORF 23 Start: 19393 End: 19497 ORF 24 Start: 24869 End: 25012 ORF 24 Start: 23272 End: 23415 ORF 24 Start: 19946 End: 20044 ORF 25 Start: 25760 End: 25810 ORF 25 Start: 24093 End: 24293 ORF 25 Start: 23239 End: 23382 ORF 26 Start: 27128 End: 27172 (-) ORF 26 Start: 24899 End: 25042 ORF 26 Start: 24863 End: 25006 ORF 27 Start: 27340 End: 27582 (-) ORF 27 Start: 27152 End: 27196 (-) ORF 27 Start: 27006 End: 27164 ORF 28 Start: 27586 End: 27708 (-) ORF 28 Start: 27326 End: 27583 (-) ORF 28 Start: 27268 End: 27522 (-) ORF 29 Start: 27721 End: 27888 ORF 29 Start: 27593 End: 27715 (-) ORF 29 Start: 28059 End: 28133 (-) ORF 30 Start: 28743 End: 29108 (-) ORF 30 Start: 28126 End: 28200 (-) ORF 30 Start: 28424 End: 28465 (-) ORF 31 Start: 28528 End: 28569 (-) ORF 31 Start: 28534 End: 28683 (-) ORF 32 Start: 28891 End: 29274 (-) ORF 32 Start: 28779 End: 29153 (-) (-) indicates that the ORF is coded on the reverse DNA strand - The % sequence identity of the DNA sequences in the ORFs between the three bacteriophage is shown in Table 6:
-
TABLE 6 % sequence identity of each ORF between the three phage 103609, 103672 & 1894; ORF Identity (%) 1 62.7* 2 90.3 3 90.0 4 90.0 5 88.6 6 91.9 7 95.2 8 93.1 9 94.8 10 90.8 11 92.5 12 96.3 13 98.6 14 90.1 15 92.7 16 93.5 17 96.5 18 66.9 19 79.7 20 87.4 21 85.2 22 96.4 23 97.2 24 92.3 25 86.0 26 62.2 27 79.8 28 77.9 29 65.9 30 86.8 31 — 32 — *ORF1 for 1894 is over 100 nucleotides longer than for either 103609 or 103672. -
FIG. 5 shows the outcome of a sequence homology analysis between 103609, 103672 and 1894, in which similarity level of 1.0 indicates 100% identity, with similarity falling according to the nature and number of differences between the three sequences. This analysis demonstrates that overall sequence identity between all of these three phage is 86.1%. -
FIG. 6 shows the results of a similar analysis between these three phage and PA6, a bacteriophage which does not show the desired characteristic of being incapable of sustaining lysogeny in a bacterium (see results Section III above). This analysis demonstrates that overall sequence identity between all of these four phage is 80.1%. Overall sequence identity between 1894 and PA6 is 87.4%, between 103609 and PA6 is 86.8% and between 103672 and PA6 is 87.3%. -
FIG. 6 clearly shows that there are two regions of low or zero % sequence identity when the DNA sequences of the threephage FIGS. 7 and 8 show that this is the result of the presence of nucleotide sequences in PA6 which are not present in any of the other three phage. - Referring to nucleotide sequence numbering according to that shown in
FIGS. 7 and 8 , nucleotides 19804-10843 of PA6 are shown as SEQ ID NO: 9; nucleotides 19876-19901 of PA6 are shown as SEQ ID NO:10; nucleotides 19913-19969 of PA6 are shown as SEQ ID NO:11; nucleotides 19979-20054 of PA6 are shown as SEQ ID NO:12; and nucleotides 26242-26620 of PA6 are shown as SEQ ID NO:13. - Without wishing to be bound by theory, although these DNA inserts are present in PA6 in non-ORF regions of the genome, the presence of such large additional DNA inserts could have an effect on the overall structure of the genome and could affect, for example, the efficacy of expression of the ORF regions.
- VI. Utilising
Bacteriophage 103672 as an Anti-P. acnes Treatment -
Bacteriophage 103672 was tested against P. acnes bacteria immediately after isolation of the bacteria from a volunteer's skin, as outlined in Method 3.4 above. The results are as shown in Table 7: -
TABLE 7 Results of incubation of P. acnes isolated from the skin of a volunteer, in the absence or presence of bacteriophage 103672Initial propionibacterial Final count, Final count, count, cfu ml−1 cfu cm−2 cfu cm−2 (Phage:cell ratio) (control) (+103672) 1.585 × 105 (6:1) Too much 0 growth to quantify - This clearly shows the efficacy of the bacteriophage against P. acnes directly isolated from the skin of the patients and demonstrates the usefulness of such bacteriophage as an anti-P. acnes agent, whether directly within a method of treatment of acne or as an ingredient in a medicament for use in such a method.
Claims (72)
1. A bacteriophage capable of lysing a P. acnes bacterium and incapable of lysing any bacterium which is not P. acnes, and which is incapable of sustaining lysogeny in a bacterium.
2. A bacteriophage according to claim 1 which lacks the ability to express at least one gene necessary for sustaining lysogeny.
3. A bacteriophage according to claim 2 having a genome which lacks all or part of at least one gene necessary for sustaining lysogeny.
4. A bacteriophage according to claim 1 having a genome which comprises defects in non-coding regions which affect the ability of the phage to sustain lysogeny.
5. An isolated bacteriophage according to claim 1 which is naturally occurring.
6. A bacteriophage according to claim 1 capable of lysing a plurality of strains of the P. acnes bacterium.
7. A bacteriophage according to claim 1 capable of lysing at least 5 strains of the P. acnes bacterium.
8. A bacteriophage according to claim 1 which is isolated and selected from: 103609 (Accession no. NCIMB 41350); 103672 (Accession no. NCIMB 41351); and 1894 (Accession no. NCIMB 41349).
9. A bacteriophage according to claim 1 having a genome having sequence identity of at least 88% with the genome of the bacteriophage deposited under Accession No. NCIMB 41349.
10. A bacteriophage according to claim 1 having a genome which comprises the DNA sequence of SEQ ID NO: 5, a genome having at least 88% sequence identity with the DNA sequence of SEQ ID NO:5, or a genome which comprises a functional fragment of the DNA sequence of SEQ ID NO: 5.
11. A bacteriophage according to claim 10 wherein the functional fragment is selected from within the Open Reading Frames shown in FIG. 4 .
12. A bacteriophage according to claim 10 wherein the functional fragment comprises a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:8.
13. A bacteriophage according to claim 10 wherein the functional fragment comprises the DNA sequence of SEQ ID NO:8.
14. An isolated bacteriophage according to claim 1 which is 1894.
15. A bacteriophage according to claim 1 having a genome having sequence identity of at least 87% with the genome of the bacteriophage deposited under Accession No. NCIMB 41350.
16. A bacteriophage according to claim 1 having a genome which comprises the DNA sequence of SEQ ID NO: 3, a genome having at least 87% sequence identity with the DNA sequence of SEQ ID NO:3, or a genome which comprises a functional fragment of the DNA sequence of SEQ ID NO: 3.
17. A bacteriophage according to claim 16 wherein the functional fragment is selected from within the Open Reading Frames shown in FIG. 2 .
18. A bacteriophage according to claim 16 wherein the functional fragment comprises a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:6.
19. A bacteriophage according to claim 16 wherein the functional fragment comprises the DNA sequence of SEQ ID NO:6.
20. A bacteriophage according to claim 1 which is 103609.
21. A bacteriophage according to claim 1 having a genome having sequence identity of at least 88% with the genome of the bacteriophage deposited under Accession No. NCIMB 41351.
22. A bacteriophage according to claim 1 having a genome which comprises the DNA sequence of SEQ ID NO: 4, a genome having at least 88% sequence identity with the DNA sequence of SEQ ID NO:4, or a genome which comprises a functional fragment of the DNA sequence of SEQ ID NO: 4.
23. A bacteriophage according to claim 22 wherein the functional fragment is selected from the Open Reading Frames shown in FIG. 3 .
24. A bacteriophage according to claim 22 wherein the functional fragment comprises a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:7.
25. A bacteriophage according to claim 22 wherein the functional fragment comprises the DNA sequence of SEQ ID NO:7.
26. A bacteriophage according to claim 1 which is 103672.
27. A bacteriophage according to claim 1 having a genome which does not comprise the DNA sequence of SEQ ID NO:9.
28. A bacteriophage according to claim 1 having a genome which does not comprise the DNA sequence of SEQ ID NO:10.
29. A bacteriophage according to claim 1 having a genome which does not comprise the DNA sequence of SEQ ID NO:11.
30. A bacteriophage according to claim 1 having a genome which does not comprise the DNA sequence of SEQ ID NO:12.
31. A bacteriophage according to claim 1 having a genome which does not comprise the DNA sequence of SEQ ID NO:13.
32. A bacteriophage according to claim 1 modified to comprise a marker molecule.
33. An isolated polynucleotide having the nucleotide sequence of the genome of a bacteriophage according to claim 1 .
34. An isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 or of a functional fragment of the DNA sequence of SEQ ID NO:3, wherein a bacteriophage comprising the polynucleotide is a bacteriophage according to claim 1 .
35. An isolated polynucleotide having sequence identity of at least 87% with the DNA sequence of SEQ ID NO:3, wherein a bacteriophage comprising the polynucleotide is a bacteriophage according to claim 1 .
36. An isolated polynucleotide according to claim 34 wherein the functional fragment is selected from within the Open Reading Frames shown in FIG. 2 .
37. An isolated polynucleotide according to claim 34 wherein the functional fragment comprises a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:6.
38. An isolated polynucleotide according to claim 36 wherein the functional fragment comprises the DNA sequence of SEQ ID NO:6.
39. An isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:4 or of a functional fragment of the DNA sequence of SEQ ID NO:4, wherein a bacteriophage comprising the polynucleotide is a bacteriophage according to claim 1 .
40. An isolated polynucleotide having sequence identity of at least 88% with the DNA sequence of SEQ ID NO:4, wherein a bacteriophage comprising the polynucleotide is a bacteriophage according to claim 1 .
41. An isolated polynucleotide according to claim 39 wherein the functional fragment is selected from within the Open Reading Frames shown in FIG.
42. An isolated polynucleotide according to claim 39 wherein the functional fragment comprises a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:7.
43. An isolated polynucleotide according to claim 41 wherein the functional fragment comprises the DNA sequence of SEQ ID NO:7.
44. An isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 or of a functional fragment of the DNA sequence of SEQ ID NO:5, wherein a bacteriophage comprising the polynucleotide is a bacteriophage according to claim 1 .
45. An isolated polynucleotide having sequence identity of at least 88% with the DNA sequence of SEQ ID NO:5, wherein a bacteriophage comprising the polynucleotide is a bacteriophage according to claim 1 .
46. An isolated polynucleotide according to claim 44 wherein the functional fragment is selected from within the Open Reading Frames shown in FIG. 4 .
47. An isolated polynucleotide according to claim 44 wherein the functional fragment comprises a DNA sequence having sequence identity of at least 95% with the DNA sequence of SEQ ID NO:8.
48. An isolated polynucleotide according to claim 46 wherein the functional fragment comprises the DNA sequence of SEQ ID NO:8.
49. An isolated polynucleotide according to claim 33 having a nucleic acid sequence which does not comprise that of SEQ ID NO:9.
50. An isolated polynucleotide according to claim 33 having a nucleic acid sequence which does not comprise that of SEQ ID NO:10.
51. An isolated polynucleotide according to claim 33 having a nucleic acid sequence which does not comprise that of SEQ ID NO:11.
52. An isolated polynucleotide according to claim 33 having a nucleic acid sequence which does not comprise that of SEQ ID NO:12.
53. An isolated polynucleotide according to claim 33 having a nucleic acid sequence which does not comprise that of SEQ ID NO:13.
54. An isolated polynucleotide having a nucleic acid sequence which is complementary to that of the polynucleotide defined in claim 33 .
55. An isolated polynucleotide comprising the polynucleotide according to claim 33 and a nucleic acid sequence encoding a marker molecule.
56. An isolated polypeptide having an amino acid sequence encoded by the polynucleotide according to claim 33 .
57. A composition comprising at least one bacteriophage according to claim 1 and an adjuvant, carrier or vehicle.
58. A composition according to claim 57 comprising two or more different bacteriophage.
59. A composition according to claim 58 wherein each of the two or more bacteriophage is a bacteriophage as defined above.
60. A composition comprising an isolated polynucleotide according to claim 33 and/or an isolated polypeptide as defined above and an adjuvant, carrier or vehicle.
61. A composition according to claim 57 in a form suitable for oral, intravenous or topical administration.
62. A composition according to claim 57 which further comprises at least one further agent selected from antibiotics, anti-comedonals, anti-P. acnes agents, anti-inflammatories and anti-seborrhoeics.
63. A composition according to claim 57 for use in the prevention or treatment of acne and wherein each at least one bacteriophage is present in an effective amount.
64. A composition according to claim 57 for use in the prevention or treatment of acne and wherein the isolated polynucleotide and/or the isolated polypeptide is present in an effective amount.
65. A method of preventing or treating acne comprising administering an effective amount of at least one bacteriophage according to claim 1 to an individual in need of such prevention or treatment.
66. A method of preventing or treating acne comprising administering an effective amount of an isolated polynucleotide according to claim 33 and/or an isolated polypeptide as defined above and/or of a composition as defined above to an individual in need of such prevention or treatment.
67. A method of improving the appearance of an individual comprising administering to the individual an effective amount of at least one bacteriophage according to claim 1 .
68. A method of improving the appearance of an individual comprising administering to the individual an effective amount of an isolated polynucleotide according to claim 33 and/or an isolated polypeptide as defined above and/or of a composition as defined above.
69. A method for isolating a bacteriophage capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and is incapable of sustaining lysogeny in a bacterium, comprising:
a) obtaining a sample of bacteria from a skin surface:
b) isolating from the sample bacteriophage which lyse propionibacteria;
c) testing the bacteriophage to determine if it is capable of lysing at least one P. acnes strain;
d) testing the bacteriophage to determine if it is capable of lysing non-P. acnes bacterial strains;
e) testing the bacteriophage to determine whether it is capable of sustaining lysogeny in a P. acnes strain;
f) isolating a bacteriophage which has been shown in steps (c), (d) and (e) to be capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes, and incapable of sustaining lysogeny in a bacterium.
70. A method for identifying a bacteriophage which is capable of lysing a P. acnes bacterium, incapable of lysing any bacterium which is not P. acnes and incapable of sustaining lysogeny in a bacterium, comprising:
a) exposing a P. acnes bacterium to the bacteriophage and determining that the bacterium is lysed;
b) exposing at least three different species of bacteria which are not P. acnes bacteria to the bacteriophage and determining that the bacteria are not lysed;
c) determining that the bacteriophage is not capable of sustaining lysogeny in a bacteria.
71. A bacteriophage isolated using the method according to claim 69 or identified using the method as defined above.
72. A bacteriophage obtainable using the method according to claim 69 or identifiable using a method as defined above.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/216,074 US20090047254A1 (en) | 2005-07-12 | 2008-06-30 | Bacteriophage and their uses |
US12/654,176 US9068159B2 (en) | 2005-07-12 | 2009-12-11 | Bacteriophage and their uses |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0514324.3 | 2005-07-12 | ||
GB0514324A GB0514324D0 (en) | 2005-07-12 | 2005-07-12 | Bacteriophage and their uses |
GB0525552.6 | 2005-12-15 | ||
GB0525552A GB0525552D0 (en) | 2005-12-15 | 2005-12-15 | Bacteriophage and their uses |
US11/483,178 US7405066B2 (en) | 2005-07-12 | 2006-07-10 | Bacteriophage and their uses |
US12/216,074 US20090047254A1 (en) | 2005-07-12 | 2008-06-30 | Bacteriophage and their uses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/483,178 Continuation US7405066B2 (en) | 2005-07-12 | 2006-07-10 | Bacteriophage and their uses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/654,176 Continuation US9068159B2 (en) | 2005-07-12 | 2009-12-11 | Bacteriophage and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090047254A1 true US20090047254A1 (en) | 2009-02-19 |
Family
ID=36974697
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/483,178 Active US7405066B2 (en) | 2005-07-12 | 2006-07-10 | Bacteriophage and their uses |
US12/216,074 Abandoned US20090047254A1 (en) | 2005-07-12 | 2008-06-30 | Bacteriophage and their uses |
US12/654,176 Active 2029-09-08 US9068159B2 (en) | 2005-07-12 | 2009-12-11 | Bacteriophage and their uses |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/483,178 Active US7405066B2 (en) | 2005-07-12 | 2006-07-10 | Bacteriophage and their uses |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/654,176 Active 2029-09-08 US9068159B2 (en) | 2005-07-12 | 2009-12-11 | Bacteriophage and their uses |
Country Status (6)
Country | Link |
---|---|
US (3) | US7405066B2 (en) |
EP (1) | EP1907534B2 (en) |
JP (1) | JP5127708B2 (en) |
AU (1) | AU2006268420B2 (en) |
CA (1) | CA2614800C (en) |
WO (1) | WO2007007055A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150141385A (en) * | 2014-06-10 | 2015-12-18 | 경북대학교 산학협력단 | Bacteriophage that kills Propionibacterium acnes |
JP2021024804A (en) * | 2019-08-05 | 2021-02-22 | 日生バイオ株式会社 | Keratin plug remover |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1907534B2 (en) * | 2005-07-12 | 2024-04-10 | Micreos B.V. | Bacteriophage and their uses |
WO2009101615A1 (en) * | 2008-02-12 | 2009-08-20 | Technion Research & Development Foundation Ltd. | Methods and compositions for controlling body odor |
US20100092431A1 (en) * | 2008-05-15 | 2010-04-15 | Auburn University | Edwardsiella Ictaluri Bacteriophage and Uses Thereof |
WO2013142378A1 (en) | 2012-03-17 | 2013-09-26 | The Regents Of The University Of California | Fast diagnosis and personalized treatments for acne |
US10351452B2 (en) | 2014-01-29 | 2019-07-16 | Synphagen Llc | Compositions for in vivo expression of therapeutic sequences in the microbiome |
WO2015116531A1 (en) * | 2014-01-29 | 2015-08-06 | Synphagen Llc. | Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses |
GB201402139D0 (en) | 2014-02-07 | 2014-03-26 | Fixed Phage Ltd | Treatment of topical and systemic bacterial infections |
WO2016130024A1 (en) * | 2015-02-13 | 2016-08-18 | Supreme Biotechnologies Limited | Endolysin expression platform |
US20170157186A1 (en) * | 2015-12-02 | 2017-06-08 | Smart Phage, Inc. | Phage to treat bacteria on skin |
US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
JP2019514885A (en) | 2016-04-21 | 2019-06-06 | ネイキッド バイオーム,インク. | Compositions and methods for the treatment of skin disorders |
KR20190039473A (en) * | 2016-05-15 | 2019-04-12 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Compositions and methods for the treatment of acne |
CN107794247A (en) * | 2016-08-31 | 2018-03-13 | 广州金羿噬菌体生物技术有限公司 | One plant of propionibacterium acnes bacteriophage and its application |
US20200121744A1 (en) * | 2016-11-08 | 2020-04-23 | The Regents Of The University Of California | Compositions and methods for treating skin diseases and maintaining healthy skin |
CN110799203A (en) * | 2017-04-21 | 2020-02-14 | Phi治疗股份有限公司 | Compositions comprising propionibacterium acnes bacteriophage for treating acne |
CA3084952A1 (en) * | 2017-12-05 | 2019-06-13 | Biomx Ltd. | Bacteriophage treatment for acne and biofilms |
CN111254122B (en) * | 2020-03-12 | 2021-12-31 | 青岛诺安百特生物技术有限公司 | Staphylococcus phage composition and application thereof in medicines for preventing and treating staphylococcus infection diseases |
CN112210503B (en) * | 2020-08-03 | 2022-05-31 | 华南农业大学 | Bacterial strain of non-pathogenic ralstonia solanacearum transformed with bacteriophage trp574 gene and preparation method and application thereof |
WO2022096596A1 (en) * | 2020-11-04 | 2022-05-12 | Eligo Bioscience | Cutibacterium acnes recombinant phages, method of production and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121036A (en) * | 1996-04-15 | 2000-09-19 | Ghanbari; Hossein A. | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
US20040241825A1 (en) * | 2001-04-19 | 2004-12-02 | Rosemonde Mandeville | Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages |
US20050032036A1 (en) * | 2001-07-18 | 2005-02-10 | Beata Weber-Dabrowska | Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections |
US7405066B2 (en) * | 2005-07-12 | 2008-07-29 | The University Of Leeds | Bacteriophage and their uses |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8918983D0 (en) * | 1989-08-21 | 1989-10-04 | Unilever Plc | Composition for hygiene purposes |
EP1250053A2 (en) * | 2000-01-11 | 2002-10-23 | Intralytix Inc. | Method for produce sanitation using bacteriophages |
JP2004520803A (en) * | 2000-04-21 | 2004-07-15 | コリクサ コーポレイション | Compositions and methods for the treatment and diagnosis of acne vulgaris |
AU2001265009A1 (en) * | 2000-05-24 | 2001-12-03 | Curagen Corporation | Human polynucleotides and polypeptides encoded thereby |
WO2002007742A2 (en) * | 2000-07-25 | 2002-01-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacteriophage having multiple host range |
GB0207021D0 (en) * | 2002-03-25 | 2002-05-08 | Univ Warwick | Anti-bacterial agents |
AU2003226499A1 (en) † | 2002-03-25 | 2003-10-08 | University Of Warwick | Bacteriophages useful for therapy and prophylaxis of bacterial infections |
CA2533352C (en) | 2003-07-23 | 2016-01-19 | Biocontrol Limited | Bacteriophage-containing therapeutic agents |
-
2006
- 2006-07-07 EP EP06755735.5A patent/EP1907534B2/en active Active
- 2006-07-07 WO PCT/GB2006/002520 patent/WO2007007055A1/en active Application Filing
- 2006-07-07 JP JP2008520941A patent/JP5127708B2/en not_active Expired - Fee Related
- 2006-07-07 CA CA2614800A patent/CA2614800C/en active Active
- 2006-07-07 AU AU2006268420A patent/AU2006268420B2/en active Active
- 2006-07-10 US US11/483,178 patent/US7405066B2/en active Active
-
2008
- 2008-06-30 US US12/216,074 patent/US20090047254A1/en not_active Abandoned
-
2009
- 2009-12-11 US US12/654,176 patent/US9068159B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121036A (en) * | 1996-04-15 | 2000-09-19 | Ghanbari; Hossein A. | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
US20040241825A1 (en) * | 2001-04-19 | 2004-12-02 | Rosemonde Mandeville | Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages |
US20050032036A1 (en) * | 2001-07-18 | 2005-02-10 | Beata Weber-Dabrowska | Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections |
US7405066B2 (en) * | 2005-07-12 | 2008-07-29 | The University Of Leeds | Bacteriophage and their uses |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150141385A (en) * | 2014-06-10 | 2015-12-18 | 경북대학교 산학협력단 | Bacteriophage that kills Propionibacterium acnes |
KR101689033B1 (en) | 2014-06-10 | 2016-12-22 | 경북대학교 산학협력단 | Bacteriophage that kills Propionibacterium acnes |
JP2021024804A (en) * | 2019-08-05 | 2021-02-22 | 日生バイオ株式会社 | Keratin plug remover |
JP7015064B2 (en) | 2019-08-05 | 2022-02-02 | 日生バイオ株式会社 | Keratin plug remover |
Also Published As
Publication number | Publication date |
---|---|
AU2006268420A1 (en) | 2007-01-18 |
EP1907534A1 (en) | 2008-04-09 |
CA2614800C (en) | 2018-10-30 |
JP2009501018A (en) | 2009-01-15 |
US20070014770A1 (en) | 2007-01-18 |
AU2006268420B2 (en) | 2012-06-28 |
EP1907534B2 (en) | 2024-04-10 |
EP1907534B1 (en) | 2013-08-07 |
US7405066B2 (en) | 2008-07-29 |
US9068159B2 (en) | 2015-06-30 |
CA2614800A1 (en) | 2007-01-18 |
WO2007007055A1 (en) | 2007-01-18 |
JP5127708B2 (en) | 2013-01-23 |
US20100226890A1 (en) | 2010-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9068159B2 (en) | Bacteriophage and their uses | |
US10953053B2 (en) | Methods and compositions for preventing infection by a Vibrio species | |
Lin et al. | Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella pneumoniae: implication in typing and treatment | |
Leshkasheli et al. | Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant Acinetobacter baumannii bacteraemia | |
Wang et al. | Protective and therapeutic application of the depolymerase derived from a novel KN1 genotype of Klebsiella pneumoniae bacteriophage in mice | |
JP2000508322A (en) | Compositions containing bacteriophages and methods of using bacteriophages to treat infectious diseases | |
Guang-Han et al. | Experimental phage therapy for Burkholderia pseudomallei infection | |
KR101261873B1 (en) | Bacteriophage having bacteriocidal effect on Salmonella spp., the cause of sitotoxism | |
KR20090030532A (en) | Bacteriophage belonging to siphoviridae and bacteriocidal composition comprising the same | |
JP2023182703A (en) | Therapeutic bacteriophage compositions for treating staphylococcus infection | |
Tang et al. | Phage resistance formation and fitness costs of hypervirulent Klebsiella pneumoniae mediated by K2 capsule-specific phage and the corresponding mechanisms | |
Zhang et al. | Therapeutic evaluation of the Acinetobacter baumannii phage Phab24 for clinical use | |
KR101291052B1 (en) | Method for prevention and treatment of Salmonella Typhimurium infection | |
KR20190138025A (en) | Novel Streptococcus suis bacteriophage Str-SUP-1 and its use for preventing proliferation of Streptococcus suis | |
KR101940019B1 (en) | Lytic bacteriophage specific for klebsiella genus resistant to antibiotics | |
Al-Madboly et al. | Characterization and genomic analysis of novel bacteriophage NK20 to revert colistin resistance and combat pandrug-resistant Klebsiella pneumoniae in a rat respiratory infection model | |
Laddika et al. | Isolation and Partial Characterisation of Streptococcus suis Bacteriophage | |
Tai et al. | Application of bacteriophage cocktail to control multi-drug resistant Pseudomonas aeruginosa | |
CA3223164A1 (en) | Bacteriophages against vancomycin-resistant enterococci | |
EP3816280A1 (en) | Coliphages and uses thereof | |
Chumsen et al. | Isolation and characterization of lytic bacteriophages against multidrug resistant Escherichia coli | |
Ghatbale et al. | In-vitro resensitization of multidrug resistant clinical isolates of Enterococcus faecium and faecalis through phage-antibiotic synergy | |
McCullor | Bacteriophage and Phage-Like Elements of Clinically Important Streptococci: Role in Horizontal Gene Transfer and Enhanced Virulence | |
Almaghrabi | Isolation and characterisation of bacteriophages that infect capsulated Streptococcus pneumonia | |
CA3217216A1 (en) | Bacteriophage therapy against adherent-invasive escherichia coli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |